Flagellin-based agents and uses including effective vaccination

ABSTRACT

The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 16/414,403 (now U.S. Pat. No. 10,730,915), filed May 16, 2019, whichis a continuation application of U.S. application Ser. No. 15/500,133(now U.S. Pat. No. 10,336,793), filed on Jan. 30, 2017, which is anational stage entry of International Patent Application No.PCT/US2015/042887, filed Jul. 30, 2015, which claims the benefit of U.S.Provisional Patent Application No. 62/031,116, filed Jul. 30, 2014;62/110,744, filed Feb. 2, 2015; and 62/117,366, filed Feb. 17, 2015, theentire contents of which are herein incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to, inter alia, new compositions andmethods for vaccination, including adjuvants comprising flagellin-basedagents.

DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

The contents of the text file submitted electronically herewith areincorporated herein by reference in their entirety: A computer readableformat copy of the Sequence Listing (filename: CLE019PCSequenceListing.txt; date recorded: Jul. 24, 2015; file size: 261 KB).

BACKGROUND

Vaccines are one of the most effective preventative health toolsavailable against infectious diseases, cancers, and allergies.Vaccination aims to generate a strong immune response to theadministrated antigen and provide long-term protection against adisorder. Often, however, an antigen alone is insufficient to stimulateprotective immunity.

Vaccine adjuvants are compounds that enhance the specific immuneresponses against antigens in vaccines. Currently, several hundrednatural and synthetic compounds are known to have adjuvant activity butonly alum salts and AS04 are licensed for use in humans in the UnitedStates. This limited list of adjuvants is insufficient for meeting thefunctional needs of effective vaccination. For example, although alum isable to induce a good T_(H2) response, it has little capacity tostimulate cellular (T_(H1)) immune responses which are so important forprotection against many pathogens.

Accordingly, there remains a need for improved vaccines and/or adjuvantsthat can effectively stimulate a subject's immune response.

SUMMARY OF THE INVENTION

Accordingly, in some aspects, the present invention provides forimproved vaccines and/or adjuvants.

In some aspects, the present invention provides a vaccine composition,comprising an adjuvant comprising a flagellin-based agent, such as, forexample, CBLB502 (a/k/a entolimod) as well as any of the flagellin-basedagents or derivatives described herein (e.g. Table 1), and an aluminumgel or salt and an antigen and, optionally, an additional adjuvant. Insome aspects, the present invention provides an adjuvant composition,comprising an adjuvant comprising a flagellin-based agent, includingCBLB502 as well as any of the flagellin-based agents or derivativesdescribed herein (e.g. Table 1), and an aluminum gel or salt. In variousembodiments, the vaccine described herein causes an improvement inadjuvant properties relative to a vaccine comprising the antigen and thealuminum gel or salt alone. In various embodiments, the vaccine and/oradjuvant described herein causes a broader, more diverse, more robustand longer lasting immunostimulatory effect than the vaccine comprisingthe antigen and the aluminum gel or salt alone and/or the adjuvantcomprising the aluminum gel or salt alone. In various embodiments, thevaccine and/or adjuvant described herein causes immunostimulation of oneor more of T_(H1) and T_(H2)-mediated immune response (e.g. both ofT_(H1) and T_(H2)-mediated immune response) and/or the vaccine and/oradjuvant described herein causes immunostimulation of T_(H1)-mediatedimmune response at levels greater than a vaccine comprising the antigenand the aluminum gel or salt alone and/or the adjuvant comprising thealuminum gel or salt alone.

In some embodiments, the flagellin-based agent may be a flagellinmolecule or flagellin-based agent, or variants thereof that has TLR5agonist activity. The flagellin-based agent may comprise one or more ofthe sequences of Table 1 (SEQ ID Nos.: 1-252), or variants thereof thathave TLR5 agonist activity and can include a variant of Salmonelladublin wild type flagellin (SEQ ID No: 1), CBLB502 (SEQ ID NO: 2) orvariants thereof (including closely-related variants such as S33ML (SEQID NO: 35), CBLB502-485CT (CBLB533, SEQ ID NO: 71), and CBLB502-S33MX(SEQ ID NO: 150)) and more distantly related variants such as flagellinderivatives from a thermophilic microorganism or flagellin derivativesfrom a microorganism well-tolerated by human (e.g. SEQ ID NOs: 243-252).In some embodiments, the aluminum gel or salt is selected from aluminumhydroxide, aluminum phosphate, and potassium aluminum sulfate, andALHYDROGEL.

In various embodiments, the present vaccine composition is part of thefollowing vaccines (e.g. the antigens of these vaccines may be used asthe antigen of the present vaccines): DTP (diphtheria-tetanus-pertussisvaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib(Haemophilus influenzae type b) conjugate vaccines, Pneumococcalconjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellowfever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, HumanPapillomavirus (HPV) vaccine, Anthrax vaccine, and Rabies vaccine.

In various embodiments, the vaccine described herein is formed, in part,by mixing the flagellin-based agent and aluminum gel or salt to form astable complex, the ratio (w/w) of flagellin-based agent to aluminum gelor salt being about 1:500 or less (e.g. about 1:500, or about 1:600, orabout 1:700, or about 1:800, or about 1:900, or about 1:1000, or about1:2000, or about 1:5000). In some embodiments, the flagellin-based agentand aluminum gel or salt are mixed in a ratio that is substantiallybelow a loading capacity of the aluminum gel or salt. In someembodiments, the flagellin-based agent and antigen are adsorbed to thealuminum gel or salt.

In another aspect, the present invention provides a method ofvaccinating a subject against a disorder, comprising administering aneffective amount of a vaccine comprising an adjuvant comprising aflagellin-based agent and an aluminum gel or salt and an antigenassociated with the disorder. In another aspect, the present inventionprovides a method of immunostimulating a subject in advance of orconcurrent with vaccination, comprising administering an effectiveamount of an adjuvant comprising a flagellin-based agent and an aluminumgel or salt, wherein both T_(H1) and T_(H2)-mediated immune responsesare immunostimulated. In various embodiments the disorder is selectedfrom infectious diseases, cancer, allergy, and autoimmune diseases (byway of example, diphtheria, tetanus, pertussis, influenza, pneumonia,hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus(HPV) infection, various cancers, anthrax, rabies, JapaneseEncephalitis, meningitis, measles, mumps, rubella, gastroenteritis,smallpox, typhoid fever, varicella (chickenpox), rotavirus, andshingles).

The details of the invention are set forth in the accompanyingdescription below. Although methods and materials similar or equivalentto those described herein can be used in the practice or testing of thepresent invention, illustrative methods and materials are now described.Other features, objects, and advantages of the invention will beapparent from the description and from the claims. In the specificationand the appended claims, the singular forms also include the pluralunless the context clearly dictates otherwise. Unless defined otherwise,all technical and scientific terms used herein have the same meaning ascommonly understood by one of ordinary skill in the art to which thisinvention belongs.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B show the 13 conserved amino acids of flagellin that maybe important for TLR5 activity. FIGS. 1A and 1B show a comparison ofamino acid sequences of the conserved amino (FIG. 1A) and carboxy (FIG.1B) terminus from 21 species of bacteria. The 13 conserved amino acidsimportant for TLR5 activity are indicated by the letter “C” at thebottom of each column. The amino add sequences are identified by theiraccession numbers from TrEMBL (first letter=Q) or Swiss-Prot (firstletter=P). With respect to FIG. 1A, SEQ ID Nos: 253-273 correspond tothe sequences listed on the figure from top to bottom, respectively.With respect to FIG. 1B, SEQ ID Nos: 274-294 correspond to the sequenceslisted on the figure from top to bottom, respectively.

FIG. 2 shows ELISA data for the average response of five mouse treatmentgroups at the time point of 1 week post-boost. Panel A is total IgG,Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3.Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called“Untreated;” Group 2 is also called “OVA,” Groups 3 is also called“OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called“SA 10 μg.”

FIG. 3 shows ELISA data for the average response of five mouse treatmentgroups at the time point of 2 weeks post-boost. Panel A is total IgG,Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3.Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called“Untreated;” Group 2 is also called “OVA,” Groups 3 is also called“OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called“SA 10 μg.”

FIG. 4 shows ELISA data for the average response of five mouse treatmentgroups at the time point of 4 weeks post-boost. Panel A is total IgG,Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3.Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called“Untreated;” Group 2 is also called “OVA,” Groups 3 is also called“OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called“SA 10 μg.”

FIG. 5 shows a determination of CBLB502/ALHYDROGEL activity using acell-based NF-κB activation assay. CBLB502/ALHYDROGEL formulation (5μg/100 μl) and ALHYDROGEL control were serially diluted in assay media2000- to 13122000-fold (2.6-0.0004 μg/ml aluminium) and incubated with293-hTLR5-LacZ cells for 20 hr. Activity of β-galactosidase was measuredafter addition of cell lysis buffer and ONPG substrate and expressed asoptical density at 414 nm (OD414).

FIG. 6 shows NF-κB-inducing activity of CBLB502/ALHYDROGEL formulatedwith different CBLB502 doses. 293-hTLR5-LacZ cells were incubated withCBLB502/ALHYDROGEL suspensions prepared at CBLB502 doses ranging from2.5 to 0.00015 μg/100 μl and diluted 200-fold with media. Activity ofβ-galactosidase reporter enzyme was measured after 20 hr incubation.

FIG. 7 shows dose-response titration curves CBLB502/ALHYDROGEL generatedwith 293-hTLR5-LacZ reporter cells. CBLB502 was adsorbed to ALHYDROGELat indicated doses (20 μg/100 μl: top panel, 0.31 μg/100 μl: middlepanel and 0.078 μg/100 μl: bottom panel), serially diluted with mediaand assayed together with soluble CBLB502 standards.

FIG. 8 shows the activity of CBLB502/ALHYDROGEL (1 μg/100 μl dose)stored at 4° C. for 2 and 6 days. NF-κB-inducing activity was measuredusing 293-hTLR5-LacZ reporter cell assay.

FIG. 9 shows pharmacokinetics of CBLB502 in mouse serum aftersubcutaneous injection of a 1 μg dose of CBLB502 adsorbed to ALHYDROGEL2%. The graph shows per-group mean serum CBLB502 concentrations and SEM(standard error of the mean) for each time point.

FIG. 10 shows induction of KC, G-CSF and IL-6 following s.c.administration of a 1 μg dose of CBLB502 adsorbed to ALHYDROGEL 2%.Serum concentrations of the cytokines were determined using R&D SystemsDuoSet kits DY453 (KC, top panel), DY414 (G-CSF, middle panel) and DY406(IL-6, bottom panel). The graphs show per-group mean serum cytokineconcentrations and SEM (standard error of the mean) for each time point.

FIG. 11 shows immunopotentiating effects of a 502 adjuvant. Anti-MA IgG(μg/ml) response (panel A) and anti-502 antibody response (panel B) byELISA to TT-SMA vaccine in the presence and absence of alum or entolimod(a varying range from 0 to 20 μg) in pooled sera collected at week 2, 4and 6 post initial vaccination is shown. Data represent the levels ofantibody in the pooled samples from each group (n=5/group).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is also based, in part, on the surprisingdiscovery that flagellin-based agents, including CBLB502 and any of theflagellin-based agents (e.g. agents comprising the sequences of Table 1,including MX-33) described herein, can be mixed with aluminum gels orsalts (and, optionally antigens), in ratios well-below theloading/adsorbing capacity of the aluminum gel or salt (e.g. 1:500), andcause a broader, more diverse, more robust and longer lastingimmunostimulatory effect than the vaccine comprising the antigen and thealuminum gel or salt alone and/or the adjuvant comprising the aluminumgel or salt alone. The inventors have also surprisingly discovered thatthe immunostimulatory effect can influence both the T_(H1) andT_(H2)-mediated arms of an immune response. The inventors have alsosurprisingly discovered that low amounts of flagellin-based agents,including CBLB502 and any of the flagellin-based agents (e.g. agentscomprising the sequences of Table 1, including MX-33) relative toantigen are effective for immunostimulation.

In one aspect, the invention provides a vaccine composition, comprisingan adjuvant comprising a flagellin-based agent and an aluminum gel orsalt and an antigen and, optionally, an additional adjuvant. In oneaspect, the invention provides an adjuvant comprising a flagellin-basedagent and an aluminum gel or salt.

In some embodiments, the described vaccine causes an improvement inadjuvant properties relative to a vaccine comprising the antigen and thealuminum gel or salt alone. In various embodiments, the vaccine and/oradjuvant described herein causes a broader, more diverse, more robustand longer lasting immunostimulatory effect than the vaccine comprisingthe antigen and the aluminum gel or salt alone (or as compared to thevaccine comprising the antigen and flagellin-based agent alone) and/orthe adjuvant comprising the aluminum gel or salt alone (or as comparedto the adjuvant comprising the flagellin-based agent alone).

In some embodiments, the described vaccine and/or described adjuvantcauses immunostimulation of one or more of T_(H1) and T_(H2)-mediatedimmune response. In some embodiments, the described vaccine and/ordescribed adjuvant causes immunostimulation of both of T_(H1) andT_(H2)-mediated immune response. In some embodiments, the describedvaccine and/or described adjuvant causes immunostimulation ofT_(H1)-mediated immune response at levels greater than a vaccinecomprising the antigen and the aluminum gel or salt alone or an adjuvantcomprising the aluminum gel or salt alone.

T_(H1)-mediated immune response (or “Type 1 response”) largely involvesinteraction with macrophages and CD8+ T cells and may be linked tointerferon-γ, TNF-β, interleukin-2, and interleukin-10 production. TheT_(H1)-mediated immune response promotes cellular immune system andmaximizes the killing efficacy of the macrophages and the proliferationof cytotoxic CD8⁺ T cells. The T_(H1)-mediated immune response alsopromotes the production of opsonizing antibodies (e.g. IgG, IgM andIgA). The Type 1 cytokine IFN-γ increases the production ofinterleukin-12 by dendritic cells and macrophages, and via positivefeedback, IL-12 stimulates the production of IFN-γ in helper T cells,thereby promoting the T_(H1) profile. Interferon-γ also inhibits theproduction of cytokines such as interleukin-4, a cytokine associatedwith the Type 2 response, and thus it also acts to preserve its ownresponse.

T_(H2)-mediated immune response (or “Type 2 response”) largely involvesinteraction with B-cells, eosinophils, and mast cells and may be linkedto interleukin-4, interleukin-5, interleukin-6, interleukin-9,interleukin-10, and interleukin-13. T_(H2)-mediated immune responsepromotes humoral immune system and may stimulate B-cells intoproliferation, induce B-cell antibody class switching, and increaseneutralizing antibody production (e.g. IgG, IgM and IgA as well as IgEantibodies). Other functions of the Type 2 response include promotingits own profile using two different cytokines. Interleukin-4 acts onhelper T cells to promote the production of T_(H2) cytokines (includingitself; it is auto-regulatory), while interleukin-10 (IL-10) inhibits avariety of cytokines including interleukin-2 and IFN-γ in helper T cellsand IL-12 in dendritic cells and macrophages. The combined action ofthese two cytokines suggests that once the T cell has decided to producethese cytokines, that decision is preserved (and also encourages other Tcells to do the same).

The division is medically relevant to, inter alia and without wishing tobe bound by theory, the fact that alum adjuvants are only effective atinducing a T_(H2)-mediated response and not a T_(H1)-mediated response(see, e.g., Smith Korsholm, et al. Immunology. January 2010; 129(1):75-86, the contents of which are hereby incorporated by reference intheir entirety).

In various embodiments, the stimulation of T_(H1) and T_(H2)-mediatedimmune responses may be measured by assays known in the art, including anumber of antibody surrogate assays (e.g. ELISA and the like). Forinstance, without wishing to be bound by theory, IgG1 is associated witha T_(H2)-like response, while a T_(H1) response is associated with theinduction of IgG2a, IgG2b, and IgG3 antibodies.

In some embodiments, the described vaccine and/or described adjuvantcauses an increase in titer of one or more of IgG1, IgG2a, IgG2b, andIgG3 antibodies (e.g. relative to the adjuvant comprising the aluminumgel or salt or flagellin-based agent alone, or relative to the vaccinecomprising the antigen and the aluminum gel or salt alone (orflagellin-based agent) alone)). In some embodiments, the describedvaccine and/or described adjuvant causes a relative increase in thetiter of all of IgG1, IgG2a, IgG2b, and IgG3 antibodies. In someembodiments, the described vaccine and/or described adjuvant causes arelative increase in the titer of more IgG3 antibodies than thedescribed vaccine and/or described adjuvant in the absence of aflagellin-based agent (or the described vaccine and/or describedadjuvant in the absence of an aluminum gel or salt alone).

Accordingly, in some embodiments, the described vaccine and/or describedadjuvant causes a diversified immune response. For example, in someembodiments, the total IgG generated by the described vaccines and/oradjuvants is greater than the described vaccines and/or adjuvantswithout the flagellin-based agent.

In some embodiments, the flagellin-based agent may be a flagellinmolecule or flagellin-related polypeptide, or variants thereof that haveTLR5 agonist activity. The flagellin-based agent may be from varioussources, including a variety of Gram-positive and Gram-negativebacterial species. In some embodiments, the flagellin-based agents mayhave an amino acid sequence that is derived from any of the flagellinsfrom bacterial species that are depicted in, for example, FIG. 7 of U.S.Patent Publication No. 2003/0044429, the contents of which areincorporated herein by reference in their entirety. The flagellin-basedagent may have nucleotide sequences related to those encoding theflagellin polypeptides listed in, for example, FIG. 7 of U.S.2003/0044429, which are publicly available at sources including the NCBIGenbank database.

The flagellin-based agent may be the major component of bacterialflagellum. The flagellin-based agents may be composed of one, or two, orthree, or four, or five, or six, or seven domains or fragments thereof(see, e.g., FIG. 10 of U.S. Pat. No. 8,324,163, the contents of whichare incorporated herein by reference in their entirety). The domains maybe selected from ND0, ND1, ND2, D3, CD2, CD1, and CD0. Domains 0 (D0), 1(D1), and 2 (D2) may be discontinuous and may be formed when residues inthe amino terminus and carboxy terminus are juxtaposed by the formationof a hairpin structure. The amino and carboxy terminus comprising the D1and D2 domains may be most conserved, whereas the middle hypervariabledomain (D3) may be highly variable. The non-conserved D3 domain may beon the surface of the flagellar filament and may contain the majorantigenic epitopes. The potent proinflammatory activity of flagellin mayreside in the highly conserved N and CD1 and D2 regions.

The flagellin-based agents may be from a species of Salmonella,representative examples of which are S. typhimurium and S. dublin(encoded by GenBank Accession Number M84972). The flagellinrelated-polypeptide may be a fragment, variant, analog, homolog, orderivative of wild type flagellin (SEQ ID NO: 1), or combinationthereof. A fragment, variant, analog, homolog, or derivative offlagellin may be obtained by rational-based design based on the domainstructure of flagellin and the conserved structure recognized by TLR5.

The flagellin-based agent may be related to a flagellin polypeptide fromany Gram-positive or Gram-negative bacterial species including, but notlimited to, the flagellin polypeptides disclosed in U.S. Pat. Pub.2003/0044429, the contents of which are incorporated herein, and theflagellin peptides corresponding to the Accession numbers listed in theBLAST results shown in FIG. 7 (panels A-F) of U.S. Patent Pub.2003/0044429, or variants thereof.

In some embodiments, the flagellin-based agent comprises or consists ofany of the polypeptides or nucleic acids encoding said polypeptideslisted in Table 1. In some embodiments, the flagellin-based agent isencoded by the nucleotide sequences listed in Table 1. In a furtherembodiment, the flagellin-based agent comprises the polypeptides listedin Table 1. In some embodiments, the flagellin-based agent comprises oneor more of SEQ ID NOs.: 1-252. In some embodiments, the flagellin-basedagent comprises a flexible linker. In a further embodiment, the flexiblelinker comprises SEQ ID NO: 16. In yet a further embodiment, theflexible linker comprises SEQ ID NO: 242.

In some embodiments, the flagellin-based agent is a variant of SEQ IDNO: 1. In various embodiments, the flagellin-based agent is not SEQ IDNO: 1.

In some embodiments, the flagellin-based agent comprises or consists ofCBLB502 (SEQ ID NO: 2) or is a variant of CBLB502 (SEQ ID NO: 2). Invarious embodiments, CBLB502 provides the advantage of, inter alia,removal of epitopes that generate neutralizing anti-flagellin antibodiesand therefore allow for the surprising adjuvant properties seen here incombination with alum.

In some embodiments, the flagellin-based agent comprises mutations inepitopes recognized by neutralizing anti-CBLB502 antibodies. Theflagellin-based agent may comprise one or more mutations in the epitopesrecognized by neutralizing anti-CBLB502 antibodies which inhibit orabrogate the ability of the antibodies to neutralize the composition. Inyet a further embodiment, the flagellin-based agent comprises atruncation and mutations in one or more epitopes. In a furtherembodiment, the mutations comprise replacement of the epitope residueswith alanine. In a further embodiment, the mutated epitopes comprise oneor more of the following residues: E153, S444, T154, N440, Q142, F131,D443, N68, T447, S110, Q117, R124, D113, E120, N127, and Q128.

The flagellin-based agent may comprise insertions, deletions, transposoninsertions, and changes to any one of the D0, D1, D2, and the variableD3 domains. The D3 domain may be substituted in part, or in whole, witha hinge or linker polypeptide that allows the D1 and D2 domains toproperly fold such that the variant stimulates TLR5 activity.

In some embodiments, the flagellin-based agent may be a minimalfunctional core of a flagellin, for example, deleting residues relativeto the already shortened CBLB502 molecule. In some embodiments, theflagellin-based agent has altered amino acid identity relative to wildtype, including deletions, additions and substitutions, that provide forimproved activity. In some embodiments, the flagellin-based agent isderived from CBLB502 (SEQ ID NO: 2). In some embodiments, theflagellin-based agent comprises a truncation in one or more domains. Ina further embodiment, the flagellin-based agent comprises a deletion inan N-terminal domain. In yet a further embodiment, the flagellin-basedagent comprises a deletion in the ND0 domain. In yet a furtherembodiment, the flagellin-based agent comprises a deletion of the entireND0 domain. In a further embodiment, the flagellin-based agent comprisesa deletion in a C-terminal domain. In yet another embodiment, theflagellin-based agent comprises a deletion in the CD0 domain. In yetanother embodiment, the flagellin-based agent retains amino acids470-485 of the CD0 domain. In yet a further embodiment, theflagellin-based agent is CBLB502-S33 (SEQ ID NO: 17).

The flagellin-based agent may comprise at least 10, 11, 12, or 13 of the13 conserved amino acids shown in FIG. 1A and FIG. 1B (positions 89, 90,91, 95, 98, 101, 115, 422, 423, 426, 431, 436 and 452). The flagellinmay be at least 30-99% identical to amino acids 1-174 and 418-505 of SEQID NO: 1.

In some embodiments, the flagellin-based agent comprises a tag. In yet afurther embodiment, the tag is attached to the N-terminus of theflagellin-based agent. In yet another embodiment, the tag is attached tothe C-terminus of the flagellin-based agent.

In some embodiments, the flagellin-based agent comprises a flexiblelinker. In a further embodiment, the flexible linker comprises SEQ IDNO: 16. In yet a further embodiment, the flexible linker comprises SEQID NO:242.

In various embodiments, the flagellin-based agent is one or more of theflagellin related composition derived from SEQ ID NO: 2. In variousembodiments, the flagellin-based agent is one or more of CBLB502-S33ML(SEQ ID NO: 35), CBLB502-485CT (CBLB533, SEQ ID NO: 71), andCBLB502-S33MX (SEQ ID NO: 150).

In various embodiments, the flagellin-based agent is a flagellinderivative from a thermophilic microorganism. In various embodiments,the flagellin-based agent is a flagellin derivative from a microorganismwell-tolerated by human. In some embodiments, the flagellin-based agentis one or more of SEQ ID NOs: 243-252.

In some embodiments, a variant includes molecules that have TLR5 agonistactivity. In some embodiments, a variant includes molecules comprisingan amino acid sequence having at least about 70% (e.g. about 70%, orabout 71%, or about 72%, or about 73%, or about 74%, or about 75%, orabout 76%, or about 77%, or about 78%, or about 79%, or about 80%, orabout 81%, or about 82%, or about 83%, or about 84%, or about 85%, orabout 86%, or about 87%, or about 88%, or about 89%, or about 90%, orabout 91%, or about 92%, or about 93%, or about 94%, or about 95%, orabout 96%, or about 97%, or about 98%, or about 99%) sequence identitywith SEQ ID NO: 1 or SEQ ID NO: 2.

In some embodiments, the flagellin-based agent comprises or consists ofany of the polypeptides or nucleic acids encoding said polypeptideslisted in Table 1. In some embodiments, the flagellin-based agent isencoded by the nucleotide sequences listed in Table 1. In a furtherembodiment, the flagellin-based agent comprises one or more of thepolypeptides listed in Table 1. In some embodiments, the flagellin-basedagent comprises or consists of polypeptides encoded by either SEQ IDNOs: 69 or 70. In some embodiments, the flagellin-based agent comprisesor consists of the polypeptides of SEQ ID NO: 71, “CBLB543”. In someembodiments, the flagellin-based agent comprises or consists ofpolypeptides encoded by either SEQ ID NOs: 149 or 151. In someembodiments, the flagellin-based agent comprises or consists of thepolypeptides of SEQ ID NO: 150, “CBLB533”.

TABLE 1 Illustrative Flagellin-Based Agents SEQ Construct DNA/ ID NamePRT Species Sequence 0001 Wild type PRT SalmonellaMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLT dublinQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNGPKEATVGDLKSSFKNVTGYDTYAAGADKYRVDINSGAVVTDAAAPDKVYVNAANGQLTTDDAENNTAVDLFKTTKSTAGTAEAKAIAGAIKGGKEGDTFDYKGVTFTIDTKTGDDGNGKVSTTINGEKVTLTVADIATGAADVNAATLQSSKNVYTSVVNGQFTFDDKTKNESAKLSDLEANNAVKGESKITVNGAEYTANATGDKITLAGKTMFTIDKTASGVSTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0002 CBLB502 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAI SequenceERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0003 T7 Promoter DNA ArtificialTAATACGACTCACTATAGGGG (forward) Sequence 0004 FliC AA74-80 DNAArtificial ATTGCGCAGACCACTGAAGG (forward) Sequence 0005 Thrombin PRTArtificial LVPRGS cleavage Sequence site 0006 Enterokinase ArtificialDDDDK cleavage Sequence site 0007 NS PRT Artificial SSGLRINSAKDDA(N-terminal Sequence spoke region; Ser32 - Ala44) 0008 CS PRT ArtificialEDADYA (C-terminal Sequence spoke region; Glu464 to Ala469) 0009 linkerPRT Artificial AASAGAGQGGGGSG Sequence 0010 linker PRT ArtificialEGKSSGSGSESKST Sequence 0011 linker PRT ArtificialGGGRTSSSAASAGAGQGGGGSG Sequence 0012 linker PRT Artificial GPSG Sequence0013 linker PRT Artificial GSAGSAAGSGEF Sequence 0014 linker PRTArtificial GSPG Sequence 0015 linker PRT Artificial KESGSVSSEQLAQFRSLDSequence 0016 linker PRT Artificial SPGISGGGGGILDSMG Sequence 0017Mutant 33-485 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAAGQAIANRFTSNIMutant S33 SequenceKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0018 Mutant 33-485DNA Artificial GCAGATTCTGCAGCAGGCTGGTTGATAATCTGGCGCAGGCTAACCAGGForward Primer Sequence CBLB485 0019 Mutant 33-485 DNA ArtificialTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTT502 template Sequence sequence 0020 Mutant 33-485 DNA ArtificialCCTGGTTAGCCTGCGCCAGATTATCAACCAGCCTGCTGCAGAATCTGC Reverse Primer SequenceCBLB485 0021 Mutant 33-485 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGG of 485CTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCMutant (T7GCGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATPromoter toTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACG Stop)GCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGT TGATAA0022 Mutant 33-485 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAAGQAIANRFTSNI ExpressedSequence KGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLMutant 33-485EEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAG 0023 Mutant 450T PRT ArtificialMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTMutant 506T SequenceQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP 0024 Mutant 450T DNA ArtificialATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCMutant 506T SequenceTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCGACAAGCTTGCG 0025 Mutant 450T DNA ArtificialCGAAAGACCATATGGCAGGCCAGGCGATTGC Forward F45CT Sequence 0026 Mutant 450TDNA Artificial CGCAAGCTTGTCGACTTACGGATCCTTATCGTC Reverse R45CT Sequence0027 Mutant 450T DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGSequence of SequenceTTTAACTTTAAGAAGGAGATATACATATGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCT450T constructAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCGAC 0028 Mutant 450T PRT ArtificialMAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSD ExpressedSequence SDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLMutant 450TGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP 0029 Mutant 33GPS DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG ExpressedSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTAMutant 33MLTTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCGGACCATCAGGTCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0030 Mutant 33GPS PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ExpressedSequence LSVQATNGTNSDSDLKSIGPSGQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDMutant 33MLGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSH HHHHHG0031 Mutant 33GPS DNA Artificial GATATACATATGAGCGGGTTACGGATCAACAGForward primer Sequence FSY3CT 0032 Mutant 33GPS DNA ArtificialAGATCTCCCGGGGAATTAACATTGAACCC Reverse primer Sequence RMIMxN 0033Mutant 33GPS DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of mutantCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC 33GPSCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGGACCATCAGGTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0034 Mutant 33GPS PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ExpressedSequence LSVQATGPSGEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKMutant 33GPSSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG 0035 Mutant 33MLPRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant 330T SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETI (Fixed A)TIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG 0036 Mutant 33ML DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant 330T SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTA (Fixed A)TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0037 Mutant 33ML DNA ArtificialTCTAGACCCGGGAAGTACCGCTAACCCACTGGCTTCAATTG Forward primer Sequence F502ML0038 Mutant 33ML DNA Artificial CCAGTCATGTCGACTTAACCATGATGATGATGATGATGAGReverse primer Sequence R33CT 0039 Mutant 33ML DNA ArtificialCTCATCATCATCATCATCATGGTTAAGTCGACAAGCTTGCGGCCGCAGAGCTCGC 502 templateSequence sequence 0040 Mutant 33ML DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGT33ML construct SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0041 Mutant 33ML DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG ExpressedSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTAMutant 33MLTTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCAT CATGGTTAA0042 Mutant 33ML PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant 33ML SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0043Mutant 37CT DNA ArtificialATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATC delta ND0Sequence TCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACGGCGCGAmutant basedAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTon CBLB506TCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCGACAAGCTTGCG 0044 Mutant 37CT PRT ArtificialMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINGAKDDAAGQAIANRFTSNIKGLT delta ND0Sequence QASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDmutant basedRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGon CBLB506TILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP 0045 Mutant 37CT DNA ArtificialCTCTGGTCATATGATCAACAGCGCGAAAGACGATGC Forward F37CT Sequence 0046Mutant 37CT DNA ArtificialTCTAGAGTCGACTATTAAGCCATACCATGATGATGATGATGATGAG Reverse R37CT Sequence0047 Mutant 37CT DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTG37CT construct SequenceTTTAACTTTAAGAAGGAGATATACATATGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTTAATAGTCGAC 0048 Mutant 37CT PRTArtificialMINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQMutant 37CT SequenceATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHGMA 0049 Mutant 445 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLLTQNNLNKSQSSL 502-SY1Sequence SSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0050 Mutant 445 DNA ArtificialATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT 502-SY1Sequence GGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0051 Mutant 445 DNA ArtificialGGCAATTCAAAACCGTTTTGATTAAGCCATTACCAACCTTGG Forward Primer SequenceCBLB445 0052 Mutant 445 DNA ArtificialCCAAGGTTGGTAATGGCTTAATCAAAACGGTTTTGAATTGCC Reverse Primer SequenceCBLB445 0053 Mutant 445 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTmutant 445 SequenceTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTAA 0054 Mutant 445 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLLTQNNLNKSQSSLmutant 445 SequenceSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFD 0055 Mutant 461 DNA ArtificialCAATCTGAACTCCGCGCGTTGACGTATCTAAGATGCTGACTATGC Forward Primer SequenceCBLB461 0056 Mutant 461 DNA ArtificialGCATAGTCAGCATCTTAGATACGTCAACGCGCGGAGTTCAGATTG Reverse Primer SequenceCBLB461 0057 Mutant 461 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTMutant 461 SequenceTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTTGACGTATCTAA 0058 Mutant 461 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLLTQNNLNKSQSSLMutant 461 SequenceSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSAR 0059 Mutant 467 DNA ArtificialCGTAGCCGTATCGAAGATGCTTAATAGGCAACGGAAGTTTCTAATATG Forward Primer SequenceCBLB467 0060 Mutant 467 DNA ArtificialCATATTAGAAACTTCCGTTGCCTATTAAGCATCTTCGATACGGCTACG Reverse Primer SequenceCBLB467 0061 Mutant 467 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTMutant 467 SequenceTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTTAATAG 0062 Mutant 467 PRTArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLLTQNNLNKSQSSLMutant 467 SequenceSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDA 0063 Mutant 470CT DNAArtificialATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT CBLB502Sequence GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0064Mutant 470CT DNA Artificial CGATAAGGATCATATGGCACAAGTCATTAATACForward Primer Sequence F470CT 0065 Mutant 470CT DNA ArtificialAGATCTGTCGACTTAACCATGATGATGATGATGATGAGAACCCCGCGGAACCAGTGCATAGTReverse Primer Sequence CAGCATCTTCGATACG R470CT 0066 Mutant 470CT DNAArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTMutant 470CT SequenceTTAACTTTAAGAAGGAGATATACATATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0067 Mutant 470CT PRTArtificialMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTMutant 470CT SequenceQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPRGSHHHHHHG 0068 Mutant 485CT DNA ArtificialAGATCTCCGCGGAACCAGACCAGCCTGCTGCAGAATCTGC Reverse primer Sequence R485MC0069 Mutant 485CT DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of 485CTCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0070 Mutant 485CTDNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant 485CT SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0071 Mutant 485CT PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant 485CT SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGLVPRGSHHHHHHG 0072 Mutant 485D DNAArtificialAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGDNA template SequenceGGCAATTCAAAACCGTTTTGATTCAGCCATTACCGCCCTTGGCAATACGGTAACCAAT for deletionmutations from Mutant 485CT variant 0073 Mutant 485D PRT ArtificialNPLASIDSALSKVDAVRSSLGAIQNRFDSAITALGNTVTN PRT sequence Sequencefor deletion mutations from Mutant485 CT variant 0074 Mutant 485D DNAArtificial GTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTG Forward PrimerSequence F485D 0075 Mutant 485D DNA ArtificialCAAGGGCGGTAATGGCTGAATCAATTGCCCCCAGAGAAGAACGAAC Reverse Primer SequenceR485D 0076 Mutant 485D DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ofCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC485CT_DeltaCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAA constructCAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0077 Mutant 485D PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant 485D SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETI (CT_DeltaTIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIDSAITALGNTVTN 439-442)LNSARSRIEDADYATEVSNMSKAQILQQAGLVPRGSHHHHHHG 0078 Mutant CGD1 DNAArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant SY3CT SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0079 Mutant CGD1 PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant SY3CT SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPRGSHHHHHHG 0080 Mutant CGD1 DNA ArtificialATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGA GFPuv4Sequence TGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCATATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAA 0081 Mutant CGD1 PRT ArtificialMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVT GFPuv4Sequence TLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALLKDPNEKRDHMVLLEFVTAAGITHGMDELYK 0082 Mutant CGD1DNA ArtificialATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGAGFPuv4 mutation SequenceTGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAAC of wtTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACT Ndel siteACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAATAA 0083 Mutant CGD1 DNA ArtificialTCTAGACGGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGC Forward primerSequence FCGFP 0084 Mutant CGD1 PRT Artificial NVYIPISGKNGIKANFKIRHPRT altered Sequence GFPuv4 sequence 0085 Mutant CGD1 DNA ArtificialAGATCTCCGCGGTTTGTATAGTTCATCCATGCCATGTGTAATCCC Reverse RCGFP Sequence0086 Mutant CGD1 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of CGD1CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0087 Mutant CGD1 DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG ExpressedSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTAMutant CGD1TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0088 Mutant CGD1 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ExpressedSequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETIMutant CGD1TIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPPISGKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALLKDPNEKRDHMVLLEFVTAAGITHGMDELYKPRGSHHHHHHG 0089Mutant CPM194 DNA ArtificialATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGMutant CPM194 SequenceTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0090 Mutant CPM194 PRT ArtificialMSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYASPGSMutant CPM194 SequenceGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGLVPRG SHHHHHHG0091 Mutant CPM194 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTMutant CPM194 SequenceTTAACTTTAAGAAGGAGATATACATATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0092Mutant CPM194 DNA Artificial TCTAGACATATGAGTACCGCTAACCCACTGGCTTCAATTGForward primer Sequence FCD1 0093 Mutant CPM194 DNA ArtificialGCTTCCCGGGGATGCATAGTCAGCATCTTCGATACGGC Reverse primer Sequence RCD1J0094 Mutant CPM194 DNA Artificial GCATCCCCGGGAAGCGGGTTACGGATCAACAGCGForward primer Sequence FND1J 0095 Mutant CPM194 DNA ArtificialAGATCTCCGCGGAACCAGACCATCGTTAGCACCAACCTGGATTTTCATCT Reverse primerSequence RND1 0096 Mutant CPM217 DNA ArtificialATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGMutant CPM217 SequenceTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0097 Mutant CPM217 PRT ArtificialMSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYASPGSMutant CPM217 SequenceGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNLVPRGSHHHHHHG 0098 Mutant CPM217 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTMutant CPM217 SequenceTTAACTTTAAGAAGGAGATATACATATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTC GAC 0099Mutant CPM217 DNA ArtificialAGATCTCCGCGGAACCAGATTAACATTGAACCCATCAAGGCCAAG Reverse primer SequenceRCPM217 0100 Mutant GD1G DNA ArtificialCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTC Forward Primer Sequence FGFP770101 Mutant GD1G DNA Artificial GAAAAAGTCATGCCGTTTCATGTGATCCGGATAACGGGReverse Primer Sequence RGFP77 0102 Mutant GD1G DNA ArtificialCTGTTCCATGGCCAACACTTG FGFP54 Sequence 0103 Mutant GD1G DNA ArtificialTCTAGACATATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCC Forward primer SequenceFNGFP 0104 Mutant GD1G DNA ArtificialGGCCTATGCGGCCGCAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAaltered GFP Sequence A DNA sequence 0105 Mutant GD1G DNA ArtificialAGATCTATTAATGCGGCCTGATAGGCCTTGTTTGTCTGCCGTGATGTATACATTGTG Reverse RNGFPSequence 0106 Mutant GD1G PRT Artificial SHNVYITADKQGLSGRNM altered GFPSequence PRT sequence 0107 Mutant GD1G DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCC of GD1GCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGT constructGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAA GTCGAC0108 Mutant GD1G DNA ArtificialATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGA ExpressedSequence TGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACMutant GD1GTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0109 Mutant GD1G PRT ArtificialMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVT ExpressedSequence TLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIEMutant GD1GLKGIDFKEDGNILGHKLEYNYNSHNVYITADKQGLSGRIMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPPISGKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALLKDPNEKRDHMVLLEFVTAAGITHGMDELYKPRGSHHHHHHG 0110 Mutant MF227C DNA ArtificialCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTACMutant 470CT SequenceATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTG template0111 Mutant MF2270 PRT ArtificialLGLDGFNVNSPGISGGGGGITLINEDAAAAKKSTANPLASI Mutant 470CT Sequence template0112 Mutant MF227C DNA ArtificialAGATCTCCGCGGAACCAGTAAAGAGAGGACGTTTTGCGGAACCTGGTTTGCATAGTCAGCATReverse Primer Sequence CTTCGATACG R2YY 0113 Mutant MF227C DNAArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of MutantCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC MF227CCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0114 Mutant MF227C DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant MF227C SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT AA 0115Mutant MF2270 PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant MF2270 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYANQVPQNVLSLLVPRGSHHHHHHG 0116 Mutant MF227N DNAArtificial AGATCTCCCGGGGAACCATCGTTAGCACCAACCTGGATTTTC Reverse PrimerSequence RMF227N 0117 Mutant MF227N DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of mutantCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC MF227NCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0118 Mutant MF227N DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGmutant MF227N SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT AA 0119Mutant MF227N PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREmutant MF227N SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG 0120 Mutant MF233 DNAArtificialAGATCTCCGCGGAACCAGCAGGTTATTCTGGGTCAACAGCGACAGGCTGTTTGTATTAATGAReverse primer Sequence CTTGTGCATAGTCAGCATCTTCGATACG RM F233 0121Mutant MF233 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGof constructCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC MF233CGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0122 Mutant MF233DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG MF233Sequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0123 Mutant MF233 PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE MF233Sequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYAQVINTNSLSLLTQNNLLVPRGSHHHHHHG 0124 Mutant MF471 DNAArtificial GCTGACTATGCAACGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGCForward primer Sequence F471-77 0125 Mutant MF471 DNA ArtificialGCAGAATCTGCGCTGCAGACATAGCAGAAACTGCCGTTGCATAGTCAGC Reverse PrimerSequence R471-77 0126 Mutant MF471 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGof constructCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC MF471CGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0127 Mutant MF471DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG MF471Sequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0128 Mutant MF471 PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE MF471Sequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATAVSAMSAAQILQQAGLVPRGSHHHHHHG 0129 Mutant MF479 DNAArtificial GTTTCTAATATGTCTAAAGCGGCGATTCTGGGAGCGGCTGGTCTGGTTCCGCGGForward primer Sequence F479-83 0130 Mutant MF479 DNA ArtificialCCGCGGAACCAGACCAGCCGCTCCCAGAATCGCCGCTTTAGACATATTAGAAAC Reverse PrimerSequence R479-83 0131 Mutant MF479 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGof constructCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC MF479CGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGGCGATTCTGGGAGCGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0132 Mutant MF479DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant MF479 SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGGCGATTCTGGGAGCGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0133 Mutant MF479 PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant MF479 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAAILGAAGLVPRGSHHHHHHG 0134 Mutant N45 DNAArtificial TCTAGAGGATCCGGCAGGCCAGGCG Forward primer Sequence N45_F 0135Mutant N45 DNA Artificial CGCAAGCTTGTCGACTTAACGC Reverse R502D0 Sequence0136 Mutant N45 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGT DNASequence TTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGsequence ofCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCMutant N45GCGAAGGATCCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAAGTCGACAAGCTTGCGG 0137 Mutant N45 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPAGQAIANRFTSNIKGLTQASRNANDMutant N45 SequenceGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0138 Mutant NGD1 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCC of NGD1CAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGT constructGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0139Mutant NGD1 DNA ArtificialATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGA ExpressedSequence TGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACMutant SY3-GFPTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0140 Mutant NGD1 PRT ArtificialMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVT ExpressedSequence TLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIEMutant LKGIDFKEDGNILGHKLEYNYNSHNVYITADKQGLSGRIMSGLRINSAKDDAAGQAIANRFTSY3-GFP/ SNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQMutant NGD1QRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPRG SHHHHHHG0141 Mutant S33 DNA Artificial TCTAGAGGATCCGTCTGGTCTGCGTATCAACAGCGCForward Sequence F502_S33 0142 Mutant S33 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGT DNASequence TTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGsequence ofCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCMutant S33GCGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAAGT CGAC 0143Mutant S33 DNA ArtificialATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATMutant S33 SequenceGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0144 Mutant S33 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAAGQAIANRFTSNIMutant S33 SequenceKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0145 Mutant SY3CTDNA Artificial AGATCTCCGCGGAACCAGTGCATAGTCAGCATCTTCGATACGGCReverse primer Sequence RSY3CT 0146 Mutant SY3CT DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of SY3CTCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTC GAC 0147Mutant SY3CT DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG ExpressedSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTAMutant SY3CTTTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0148 Mutant SY3CT PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ExpressedSequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETIMutant SY3CTTIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYALVPRGSHHHHHHG 0149 Mutant 33MX DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGMutant 33MX SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCAT CATGGTTAA0150 Mutant 33MX PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGALNEINNNLQRVREMutant 33MX SequenceLSVQATAGANADAALKAIQAEIQQRLEEIDRVSQQTQAAAVKVLSQDNAMAIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSQMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0151Mutant 33MX DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of 33MXCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0152 Mutant 485MX DNAArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA Sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of 485MXCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0153 Mutant 485MXDNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG 485MXSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTAconstruct TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA 0154 Mutant 485MX PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGALNEINNNLQRVRE 485MXSequence LSVQATAGANADAALKAIQAEIQQRLEEIDRVSQQTQAAAVKVLSQDNAMAIQVGANDGAAIconstruct TIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSQMSKAQILQQAGLVPRGSHHHHHHG 0155 Mutant MIM4 DNAArtificialATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT CBLB502Sequence GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCATTAATACAAACAvariant GCCTGTCGCTGTTGACCCAGAATAACCTGCAGAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTCAAGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0156Mutant MIM4 DNA ArtificialAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGG PrimersSequence GGCAATTCAAAACCGTTTTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGGdesign (for CCTCCGCGCGTAGCGCTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGdeletion aa Gln439; Asn440; Arg441; Phe442): 0157 Mutant MIM4 PRTArtificial NPLASIDSALSKVDAVRSSLGAIQNRFDSAITALGATVTALASARSAIEDADYATEVSNMPrimers Sequence design (for deletion aa Gln439; Asn440; Arg441;Phe442): 0158 Mutant MIM4 DNA ArtificialGCAGTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTGG Forward PrimerSequence MIM4 0159 Mutant MIM4 DNA ArtificialCCAAGGGCGGTAATGGCTGAATCAATTGCCCCCAGAGAAGAACGAACTGC Reverse PrimerSequence MIM4 0160 Mutant MIM4 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTG MIM4Sequence TTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGGCCTCCGCGGCTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0161 Mutant MIM4 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAI MIM4Sequence ERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIDSAITALGATVTALASAASRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0162 Mutant MIM5 DNA ArtificialAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGG PrimersSequence GGCAATTGCAAAGGCTTTTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGGdesign CCTCCGCGCGTAGCGCTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATG(mutations Gln439Ala; Asn440Lys; Arg441Ala): 0163 Mutant MIM5 PRTArtificial NPLASIDSALSKVDAVRSSLGAIAKAFDSAITALGATVTALASARSAIEDADYATEVSNMPrimers Sequence design (mutations Gln439Ala; Asn440Lys; Arg441Ala):0164 Mutant MIM5 DNA ArtificialCGTTCTTCTCTGGGGGCAATTGCAAAGGCTTTTGATTCAGCCATTACCGC Forward PrimerSequence MIM5 0165 Mutant MIM5 DNA ArtificialGCGGTAATGGCTGAATCAAAAGCCTTTGCAATTGCCCCCAGAGAAGAACG Reverse PrimerSequence MIM5 0166 Mutant MIM5 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTG MIM5Sequence TTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTGCAAAGGCTTTTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGGCCTCCGCGGCTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0167 Mutant MIM5 PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAI MIM5Sequence ERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIAKAFDSAITALGATVTALASAASRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0168 Mutant MIMX DNA ArtificialATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATMutant 33MIMX SequenceGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAAGCTAACGGTGTTAAAGTCCTGTCTCAGGACAACGCAATGAAAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAGCTCGTTTTGCCGCGGCCATTGCTAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA 0169 Mutant MIMX PRT ArtificialMRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAAGQAIANRFTSNI MIMXSequence KGLTQASRNAADGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQANGVKVLSQDNAMKIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQARFAAAIANLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR 0170 Mutant MIMXDNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGG of 33MIMXCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAAGCTAACGGTGTTAAAGTCCTGTCTCAGGACAACGCAATGAAAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAGCTCGTTTTGCCGCGGCCATTGCTAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAAGT CGAC 0171Mutant MIXC DNA ArtificialAGATCTGTCGACTTAACCATGATGATGATGATGATGAGAACCCCGCGGAACCAGTAAAGAGAReverse primer Sequence GGACGTTTTGCGGAACC RMIXC 0172 Mutant MIXC DNAArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of MIXCCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAGCTCGTTTTGCCGCGGCCATTGCTAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0173 Mutant MIXC PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE MIXCSequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQARFAAAIANLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0174Mutant MIXN DNA ArtificialAGATCTCATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGC Forward primer SequenceFMIMxN 0175 Mutant MIXN DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTDNA sequence SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG of MIX.NCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAAGCTAACGGTGTTAAAGTCCTGTCTCAGGACAACGCAATGAAAATCCAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0176 Mutant MIXN PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGALNEINNNLQRVRE ExpressedSequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQANGVKVLSQDNAMKIQVGANDGAAIMutant MIX.NTIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0177Mutants MIM1; DNA ArtificialAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGMIM2 and MIM3 SequenceGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGA502 MutantsACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAA MIM1;GCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAAMIM2 and MIM3 CGTCCTCTCTTTACTGCGTTAA C-terminal part of CBLB502 0178Mutants MIM1; DNA ArtificialATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATMIM2 and MIM3 Sequence Primers design (mutant MIM1) 0179 Mutants MIM1;PRT Artificial ITNLGNTVTNLNSARSRIED MIM2 and MIM3 SequencePrimers design (mutant MIM1) 0180 Mutants MIM1; DNA ArtificialCCTTGGCAATACGGTAACCGCTCTGGCCTCCGCGCGTAGCCGTATC MIM2 and MIM3 SequenceForward Primer 455-57 0181 Mutants MIM1; DNA ArtificialGATACGGCTACGCGCGGAGGCCAGAGCGGTTACCGTATTGCCAAGG MIM2 and MIM3 SequenceReverse Primer 455-57 0182 Mutants MIM1; DNA ArtificialACGGTAACCGCTCTGGCCTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAMIM2 and MIM3 Sequence Primers design (mutant MIM2_MIM1 plus R460A) 0183Mutants MIM1; PRT Artificial TVTALASARSRIEDADYATE MIM2 and MIM3 SequencePrimers design (mutant MIM2_MIM1 plus R460A) 0184 Mutants MIM1; DNAArtificial GCTCTGGCCTCCGCGGCTAGCCGTATCGAAGATG MIM2 and MIM3 SequenceForward Primer 460 0185 Mutants MIM1; DNA ArtificialCATCTTCGATACGGCTAGCCGCGGAGGCCAGAGC MIM2 and MIM3 Sequence Reverse Primer460 0186 Mutants MIM1; DNA ArtificialCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCGCTCTGGCCTCCMIM2 and MIM3 Sequence Primers design (mutant MIM3_MIM2 plus N448A;N451A) 0187 Mutants MIM1; PRT Artificial QNRFDSAITNLGNTVTALASMIM2 and MIM3 Sequence Primers design (mutant MIM3_MIM2 plusN448A; N451A) 0188 Mutants MIM1; DNA ArtificialGTTTTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGG MIM2 and MIM3 SequenceForward Primer 448-51 0189 Mutants MIM1; DNA ArtificialCCAGAGCGGTTACCGTAGCGCCAAGGGCGGTAATGGCTGAATCAAAAC MIM2 and MIM3 SequenceReverse Primer 448-51 0190 Mutant ME42 DNA ArtificialCAACAGCGCGAAAGCCGATGCGGGAGGCCAGGCGATTGC Forward Primer Sequence ME420191 Mutant ME42 DNA Artificial GCAATCGCCTGGCCTCCCGCATCGGCTTTCGCGCTGTTGReverse Primer Sequence ME42 0192 Mutant ME42 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGCCGATG ME42CGGGAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0193 Mutant ME42 PRT ArtificialMSGLRINSAKADAGGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME42 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0194Mutant ME110 DNA Artificial GTCTGTTCAGGCCACTGCCGGGGCTAACTCTGATTCCGATCTGForward Primer Sequence ME100 0195 Mutant ME110 DNA ArtificialCAGATCGGAATCAGAGTTAGCCCCGGCAGTGGCCTGAACAGAC Reverse Primer SequenceME100 0196 Mutant ME110 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME100CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0197 Mutant ME110 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME110 SequenceLSVQATAGANSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0198Mutant DNA Artificial CTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCME100/110 Sequence Forward Primer ME110 0199 Mutant DNA ArtificialGACGTTGCTGAATTTCAGCCTGGATAGCTTTCAGATCGGAATCAG ME100/110 SequenceReverse Primer ME110 0200 Mutant DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGT ME100/110Sequence TTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGSequence ofCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC ME100/110CGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAA constructCAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0201 Mutant ME104N DNAArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGIntermediate SequenceCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTA MutantTTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAG ME100/110TTGTCTGTTCAGGCCACTGCCGGGGCTAACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCAT CATGGTTAA0202 Mutant PRT ArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ME100/110Sequence LSVQATAGANSDSDLKAIQAEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETIMutant TIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNME110/110 TVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG 0203 Mutant ME104 DNA ArtificialGCCACTAACGGGACTAACGCTGATGCCGCTCTGAAATCTATCCAG Forward Primer SequenceME104 0204 Mutant ME104 DNA ArtificialCTGGATAGATTTCAGAGCGGCATCAGCGTTAGTCCCGTTAGTGGC Reverse Primer SequenceME104 0205 Mutant ME104 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME104CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACGCTGATGCCGCTCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0206 Mutant ME104 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME104 SequenceLSVQATNGTNADAALKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0207Mutant ME104N DNA ArtificialGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAG Primer Sequence FME104New0208 Mutant ME104N DNA ArtificialCTGGATAGCTTTCAGAGCGGCATCAGCGTTAGCCCCGGCAGTGGC Primer Sequence RME104New0209 Mutant ME104N DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG constructCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC ME104NewCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0210 Mutant ME104N PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME104N SequenceLSVQATAGANADAALKAIQAEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0211Mutant ME110 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME110CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0212 Mutant ME110 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME110 SequenceLSVQATNGTNSDSDLKAIQAEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0213Mutant ME117 DNA ArtificialCTATCCAGGATGAAATTCAGGCACGTCTGGCAGAAATCGATCGCG Forward Primer SequenceME117 0214 Mutant ME117 DNA ArtificialCGCGATCGATTTCTGCCAGACGTGCCTGAATTTCATCCTGGATAG Reverse Primer SequenceME117 0215 Mutant ME117 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG33ML constructCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC(should thisCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAAsay ME117?)CAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGGCACGTCTGGCAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0216 Mutant ME117 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME117 SequenceLSVQATNGTNSDSDLKSIQDEIQARLAEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0217Mutant ME124 DNA ArtificialGGAAGAAATCGATGCCGTTTCTGCTGCGACTCAATTTAACGGTGTTAAAGTCCTGTCTCForward Primer Sequence ME104 0218 Mutant ME124 DNA ArtificialGAGACAGGACTTTAACACCGTTAAATTGAGTCGCAGCAGAAACGGCATCGATTTCTTCCReverse Primer Sequence ME104 0219 Mutant ME124 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME124CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATGCCGTTTCTGCTGCGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0220 Mutant ME124 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME124 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDAVSAATQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0221Mutant ME124P DNA ArtificialCAGCAACGTCTGGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTTAACGG Forward PrimerSequence ME124P 0222 Mutant ME124P DNA ArtificialCCGTTAAATTGAGTCTGATTAGAAACGGCATCGATTTCTTCCAGACGTTGCTG Reverse PrimerSequence ME124P 0223 Mutant ME124 DNA ArtificialATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCG ExpressedSequence CTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTAMutant ME124PTTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCAT CATGGTTAA0224 Mutant ME124P DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGT ME124PSequence TTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0225 Mutant ME124P PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE ME124PSequence LSVQATNGTNSDSDLKSIQDEIQQRLEEIDAVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0226Mutant ME132 DNA ArtificialCGTTTCTAATCAGACTCAATTTGCCGCTGTTAAAGTCCTGTCTCAGGACAACC Forward PrimerSequence ME132 0227 Mutant ME132 DNA ArtificialGGTTGTCCTGAGACAGGACTTTAACAGCGGCAAATTGAGTCTGATTAGAAACG Reverse PrimerSequence ME132 0228 Mutant ME132 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME132CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTGCCGCTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0229 Mutant ME132 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME117 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFAAVKVLSQDNQMKIQVGANDGETI (ME132?)TIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0230Mutant ME142 DNA ArtificialGTTAAAGTCCTGTCTCAGGACAACGCGATGGCAATCCAGGTTGGTGCTAACG Forward PrimerSequence ME142 0231 Mutant ME142 DNA ArtificialCGTTAGCACCAACCTGGATTGCCATCGCGTTGTCCTGAGACAGGACTTTAAC Reverse PrimerSequence ME142 0232 Mutant ME142 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME142CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACGCGATGGCAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0233 Mutant ME142 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME142 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNAMAIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0234Mutant ME150 DNA ArtificialGATGAAAATCCAGGTTGGTGCTAGCGCTGCTGAAACCATTACCATCGATCTGC Forward PrimerSequence ME150 0235 Mutant ME150 DNA ArtificialGCAGATCGATGGTAATGGTTTCAGCAGCGCTAGCACCAACCTGGATTTTCATC Reverse PrimerSequence ME150 0236 Mutant ME150 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME150CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAGCGCTGCTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0237 Mutant ME150 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME150 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGASAAETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0238Mutant ME468 DNA ArtificialGCCGTATCGAAGATGCTGACGCTGGAGCGGAAGTTGCTAATATGTCTAAAGCGCAG Forward PrimerSequence ME468 0239 Mutant ME468 DNA ArtificialCTGCGCTTTAGACATATTAGCAACTTCCGCTCCAGCGTCAGCATCTTCGATACGGC Reverse PrimerSequence ME468 0240 Mutant ME468 DNA ArtificialTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAATAATTTTGTSequence of SequenceTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATG ME468CGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCC constructCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACGCTGGAGCGGAAGTTGCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC 0241 Mutant ME468 PRTArtificialMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVREMutant ME468 SequenceLSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADAGAEVANMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHH HG 0242Linker PRT Artificial SPG Sequence 0243 Lru283 PRT ArtificialmghhhhhhsgMEEFNMRINTNVAAMNTYSRLTAANTAKSNSLAKLSSGLRINKAGDDAAGLA SequenceISEKMKSQIGGLTQAKRNAQDGISLVQTAEGALNETHSILERMRDLAVQGSNGTLTSSDRGSINKELKALHQELTRISNTTEFNTQKLFSQTKQKSVTFTFQIGANAGQTLSVAITAMSGEALLVSTDAKFSLNAAGTNAGAMIKSIDAAIAKVSDQRADLGAVQNRLEHTINNLTATNENLSDANSRIRDVDMAEEMMTFTKSNILSQAATSMLAQANAMPNSVLNLLQG 0244 Tpe270 PRT ArtificialmghhhhhhsgMRINHNISALNAWRNIDQTQYSMSKTLERLSSGLRINRAGDDAAGLAISEKM SequenceRGQIKGLNMAIKNAQDAISLIQTAEGALTEVHSILQRMRELAVQAASDTNTNVDREQIQKEIDQLREEIDRIARTTEFNTKKLLDGKLEGFRSQVDAKVVTGGNINVQLGTVSSKAVEGTYVIEVGaAERAIMVVDAAIHRVSTARAALGAIQNRLEHTISNLGVAAENLTAAESRIRDADMAKEMMEFTKQQILLQSSMAMLAQSNTLPQNVLQLMR 0245 Tpe159w PRT ArtificialmghhhhhhsGLNMAIKNAQDAISLIQTAEGALTEVHSILQRMRELAVQAASDTNTNVDREQI SequenceQKEIDQLREEIDRIARTTEFNTKKLLDGKLEGFRSQVDAKVVTGGNINVQLGTVSSKAVEGTYVIEVGaAERAIMVVDAAIHRVSTARAALGAIQNRLEHTISNLG 0246 Chy275 PRT ArtificialmghhhhhhsgMSLRINNNIEALNAWRALNSTSNALQKSMEKLSSGLRINRAGDDAAGLAISE SequenceKLRAQIRGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAVSTGLVVTLQVGANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLGIASENLSASESRIRDVDMAAEMMNFTKNQILQQAGVAILAQANQAPQAVLQLLR 0247 Chy162w PRT ArtificialmghhhhhhsGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAI SequenceTTELNQLFNEIDRIAGATEFNTKNLLAVSTGLVVTLQVGANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG 0248 ChyU137 PRTArtificialmghhhhhhsGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAI SequenceTTELNQLFNEIDRIAGATEFNTKNLLAAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG 0249 ChyN108 PRT ArtificialmghhhhhhSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLGpdGLNQAIRNAQDGIS SequenceLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIA 0250 ChyZ94 PRTArtificialmghhhhhhsNNQDISAITTELNQLFNEIDRIAGATgsGGLSEIQNILQRMRELGVQAANGTL SequenceNggSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG 0251 Fir161B PRT ArtificialmghhhhhhsGLAQASRNAQDAISIAQTAEGALDETQSILQRVRELGVQGANGTLTADDINAL SequenceQAEVDQLIAEIDRIAGATEFNTQNLLDGSFTTKAFQVGANSGQNMTLTIGKMDTTTLGLSSADLAINDNAFANGAISTVDSALQKVSAERAKLGAIQNRLEHTIANLG 0252 Fir161MNB PRTArtificialmghhhhhhsGLAQASRQAQDAISIAQTAEGALDETQSILQRVRELGVQGADGTLTADDIDAL SequenceQAEVDQLIAEIDRIAGATEFATQKLLDGSFTTKAFQVGAASGQDVTLTIGKVDTTTLGLSSADLAIDSAAFADGAISTVDSALQKVSAERAKLGAIQNRLEHTIAQLG

In some embodiments, the aluminum gel or salt is selected from aluminumhydroxide, aluminum phosphate, and potassium aluminum sulfate, AS04(which is composed of aluminum salt and MPL), and ALHYDROGEL. In someembodiments, the aluminum gel or salt is a formulation or mixture withany of the additional adjuvants described herein.

In some embodiments, adjuvants in addition to the describedflagellin-based agent and an aluminum gel or salt find use in thepresent invention. In some embodiments, the additional adjuvant isselected from, oil-in-water emulsion formulations, saponin adjuvants,ovalbumin, Freunds Adjuvant, cytokines, and chitosans. Illustrativeadditional adjuvants include, but are not limited to: (1) ovalbumin(e.g. ENDOFIT), which is often used for biochemical studies; (2)oil-in-water emulsion formulations (with or without other specificimmunostimulating agents such as muramyl peptides or bacterial cell wallcomponents), such as for example (a) MF59 (PCT Publ. No. WO 90/14837),containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionallycontaining various amounts of MTP-PE) formulated into submicronparticles using a microfluidizer such as, for example, Model HOymicrofluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10%Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDPeither microfluidized into a submicron emulsion or vortexed to generatea larger particle size emulsion, (c) RIBI adjuvant system (RAS), (RIBIIMMUNOCHEM, Hamilton, Mo.) containing 2% Squalene, 0.2% Tween 80, and,optionally, one or more bacterial cell wall components from the group ofmonophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wallskeleton (CWS), including MPL+CWS (DETOX™); and (d) ADDAVAX(Invitrogen); (3) saponin adjuvants, such as STIMULON (CambridgeBioscience, Worcester, Mass.) may be used or particles generatedtherefrom such as ISCOMs (immunostimulating complexes); (4) CompleteFreunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5)cytokines, such as interleukins (by way of non-limiting example, IL-1,IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g., gammainterferon), macrophage colony stimulating factor (M-CSF), tumornecrosis factor (TNF), etc; (6) chitosans and other derivatives ofchitin or poly-N-acetyl-D-glucosamine in which the greater proportion ofthe N-acetyl groups have been removed through hydrolysis (see, e.g.,European Patent Application 460 020, which is hereby incorporated byreference in its entirety, disclosing pharmaceutical formulationsincluding chitosans as mucosal absorption enhancers; and (7) othersubstances that act as immunostimulating agents to enhance theeffectiveness of the composition, e.g., monophosphoryl lipid A. In otherembodiments, the additional adjuvant is one or more of a flagellin-basedagent (e.g. CBLB502 or any of the agents of Table 1), an aluminium saltor gel, a pattern recognition receptors (PRR) agonist, CpG ODNs andimidazoquinolines. In some embodiments, the additional adjuvant is oneor more of cyclic [G(3′,5′)pA(3′,5′)p] (e.g. 3′3′-cGAMP VACCIGRADE);cyclic [G(2′,5′)pA(3′,5′)p]2′3′ (e.g. 2′3′ cGAMP VACCIGRADE); cyclic[G(2′,5′)pA(2′,5′)p] (e.g. 2′2′-cGAMP VACCIGRADE), cyclic diadenylatemonophosphate (e.g. c-di-AMP VACCIGRADE); cyclic diguanylatemonophosphate (e.g. c-di-GMP VACCIGRADE); TLR7 agonist-imidazoquinolinescompound (e.g. TLR7 agonists, such as, for example, GardiquimodVACCIGRADE, Imiquimod VACCIGRADE, R848 VACCIGRADE); lipopolysaccharides(e.g. TLR4 agonists), such as that from E. coli 0111:B4 strain (e.g.LPS-EB VACCIGRADE); monophosphoryl lipid A (e.g. MPLA-SM VACCIGRADE andMPLA Synthetic VACCIGRADE); N-glycolylated muramyldipeptide (e.g.N-Glycolyl-MDP VACCIGRADE); CpG ODN, class A and/or CpG ODN, class Band/or CpG ODN, class C (e.g. ODN 1585 VACCIGRADE, ODN 1826 VACCIGRADE,ODN 2006 VACCIGRADE, ODN 2395 VACCIGRADE), a triacylated lipoprotein(e.g. Pam3CSK4 VACCIGRADE); Polyinosine-polycytidylic acid (e.g.Poly(I:C) (HMW) VACCIGRADE); and cord factor (i.e. mycobacterial cellwall component trehalose 6,6′ dimycolate (TDM)) or an analog thereof(e.g. TDB VACCIGRADE, TDB-HS15 VACCIGRADE). In some embodiments, theadditional adjuvant is a TLR agonist (e.g. TLR1, and/or TLR2, and/orTLR3, and/or TLR4, and/or TLR5, and/or TLR6, and/or TLR7, and/or TLR8,and/or TLR9, and/or TLR10, and/or TLR11, and/or TLR12, and/or TLR13), anucleotide-binding oligomerization domain (NOD) agonist, a stimulator ofinterferon genes (STING) ligand, or related agent.

In some embodiments, the additional adjuvants is one or more of amineral adjuvant, gel-based adjuvant, tensoactive agent, bacterialproduct, oil emulsion, particulated adjuvant, fusion protein, andlipopeptide. Other mineral salt adjuvants, besides the aluminumadjuvants described elsewhere, include salts of calcium (e.g. calciumphosphate), iron and zirconium. Other gel-based adjuvants, besides thealuminum gel-based adjuvants described elsewhere, include Acemannan.Tensoactive agents include Quil A, saponin derived from an aqueousextract from the bark of Quillaja saponaria; saponins, tensoactiveglycosides containing a hydrophobic nucleus of triterpenoid structurewith carbohydrate chains linked to the nucleus, and QS-21. Bacterialproducts include cell wall peptidoglycan or lipopolysaccharide ofGram-negative bacteria (e.g. from Mycobacterium spp., Corynebacteriumparvum, C. granulosum, Bordetella pertussis and Neisseria meningitidis),N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), different compoundsderived from MDP (e.g. threonyl-MDP), lipopolysaccharides (LPS) (e.g.from the cell wall of Gram-negative bacteria), trehalose dimycolate(TDM), and DNA containing CpG motifs. Oil emulsions include FIA,Montanide, Adjuvant 65, Lipovant, the montanide family of oil-basedadjuvants, and various liposomes. Among particulated and polymericsystems, poly (DL-lactide-coglycolide) microspheres have beenextensively studied and find use herein.

Further, in some embodiments, cytokines are an adjuvant of the presentinvention (e.g. IFN-γ and granulocyte-macrophage colony stimulatingfactor (GM-CSF)). Also carbohydrate adjuvants (e.g. inulin-derivedadjuvants, such as, gamma inulin, algammulin (a combination of γ-inulinand aluminum hydroxide), and polysaccharides based on glucose andmannose, such as glucans, dextrans, lentinans, glucomannans andgalactomannans) find use in the present invention. In some embodiments,adjuvant formulations are useful in the present invention and includealum salts in combination with other adjuvants such as Lipid A,algammulin, immunostimulatory complexes (ISCOMS), which are virus likeparticles of 30-40 nm and dodecahedric structure, composed of Quil A,lipids, and cholesterol.

In some embodiments, the additional adjuvants are described in Jenningset al. Adjuvants and Delivery Systems for Viral Vaccines-Mechanisms andPotential. In: Brown F, Haaheim L R, (eds). Modulation of the ImmuneResponse to Vaccine Antigens. Dev. Biol. Stand, Vol. 92. Basel: Karger1998; 19-28 and/or Sayers et al. J Biomed Biotechnol. 2012; 2012:831486, and/or Petrovsky and Aguilar, Immunology and Cell Biology (2004)82, 488-496 the contents of which are hereby incorporated by referencein their entireties.

In various embodiments, the present adjuvants (e.g. flagellin-basedagent and an aluminum gel or salt) may be part of live and attenuated,or killed or inactivated, or toxoid, or subunit or conjugate vaccines.

In various embodiments, the present adjuvants (e.g. flagellin-basedagent and an aluminum gel or salt) may be part of one or more approvedvaccines and/or the antigens of one or more approved vaccines may be theantigens of the present invention. In some embodiments, the approvedvaccines include: Adenovirus; Anthrax (Biothrax); BCG (Tice); DT(Sanofi); DTaP (Daptacel); DTaP (Infanrix); DTaP-HepB-IPV (Pediarix);DTaP-IPV (Kinrix); DTaP-IPV/Hib (Pentacel); Hib (ActHIB); Hib (Hiberix);Hib (PedvaxHIB); Hib/Hep B (Comvax); Hib/Mening. CY (MenHibrix); Hep A(Havrix); Hep A (Havrix); Hep B (Engerix-B); Hep B (Recombivax); HepA/Hep B (Twinrix); Human Papillomavirus (HPV) (Cerverix); HumanPapillomavirus (HPV) (Gardasil); Influenza (Afluria); Influenza(Agriflu); Influenza (Fluarix); Influenza (Flublok); Influenza(Flucelvax); Influenza (Fluvirin); Influenza (Flulaval); Influenza(Fluzone: Standard, High-Dose, & Intradermal); Influenza (FluMist);Japanese Encephalitis (Ixiaro); Meningococcal (MCV4—Menactra);Meningococcal (MCV4—Menveo); Meningococcal (MPSV4—Menomune); MMR(MMR-II); MMRV (ProQuad); Pneumococcal (PCV13—Prevnar 13); PneumococcalPPSV-23—Pneumovax); Polio (IPV—Ipol); Rabies (Imovax); Rabies(RabAvert); Rotavirus (RotaTeq); Rotavirus (Rotarix); Smallpox(Vaccinia—ACAM2000); Td (Decavac); Td (Tenivac); Td (Mass Biologics);Tdap (Adacel); Tdap (Boostrix); Typhoid (inactivated—Typhim Vi); Typhoid(oral—Ty21a); Varicella (Varivax); Yellow Fever (YF—Vax); and Zoster(Shingles—Zostavax).

In various embodiments, the present adjuvants (e.g. flagellin-basedagent and an aluminum gel or salt) may be part of one or moreillustrative vaccines and/or the antigens of one or more illustrativevaccines may be the antigens of the present invention. Illustrativevaccines include, by way of example, subunit vaccine and inactivated or“killed” vaccine (e.g. Infanrix-IPV/Hib (Bordetella pertussis),Infanrix-IPV/Hib (Haemophilus influenzae), Infanrix-IPV/Hib(Poliovirus), Infanrix-IPV/Hib (Clostridium tetani), Infanrix-IPV/Hib(Corynebacterium diphtheriae), Infanrix-hexa (Bordetella pertussis),Infanrix-hexa (Haemophilus influenzae), Infanrix-hexa (Poliovirus),Infanrix-hexa (Hepatitis B virus), Infanrix-hexa (Clostridium tetani),Infanrix-hexa (Corynebacterium diphtheriae), Infanrix-IPV (Bordetellapertussis), Infanrix-IPV (Poliovirus), Infanrix-IPV (Clostridiumtetani), Infanrix-IPV (Corynebacterium diphtheriae), Infanrix/Hib(Corynebacterium diphtheriae), Pediarix (Clostridium tetani), Pediarix(Poliovirus), Pediarix (Hepatitis B virus), ViVaxim (Salmonella spp.),ViVaxim (Hepatitis A virus); subunit vaccines (e.g. 5CVMB (Neisseriameningitidis), B. pertussis CyaA protein vaccine (Bordetella pertussis),B. pertussis PTx protein vaccine (Bordetella pertussis), Cancer VEGFAprotein vaccine (Cancer), E. coli vaccine using intimin polypeptide(Escherichia coli), Engerix-B (Hepatitis B virus), H. pylori VacAprotein vaccine (Helicobacter pylori), HC of type C and D (Clostridiumbotulinum), Infanrix/Hib (Bordetella pertussis), Infanrix/Hib(Haemophilus influenzae), Infanrix/Hib (Clostridium tetani), M.gallisepticum TM-1 Protein Subunit Vaccine (Mycoplasma gallisepticum),MDA-modified human apo B-100 peptide Vaccine (Atherosclerosis), MSP3-LSPwith aluminium hydroxide (Plasmodium spp.), Mumps HN Protein SubunitVaccine (Mumps virus), N. miningitidis TBP2 Protein Vaccine (Neisseriameningitidis), P. aeruginosa Oprl Protein Vaccine (Pseudomonasaeruginosa), P. falciparum Subunit SE36 Protein Vaccine (Plasmodiumspp.), Phleum pratense Allergy Phl p 12 Subunit Vaccine (Allergy),Recombivax HB (Hepatitis B virus), S. pneumoniae ClpP protein Vaccine(Streptococcus pneumoniae); toxoid vaccine (e.g. BoNT/F(Hc) (Clostridiumbotulinum), DAPTACEL (Corynebacterium diphtheriae), Infanrix (Bordetellapertussis), Infanrix (Clostridium tetani), KINRIX (Clostridium tetani),PBT (Clostridium botulinum), Pediarix (Bordetella pertussis),inactivated or “killed” vaccines (e.g. Avaxim (Hepatitis A virus),Avaxim-Pediatric (Hepatitis A virus), FSME-IMMUN (Tick-borneEncephalitis Virus (TBEV)), Infanrix (Corynebacterium diphtheriae),Ixiaro (Japanese encephalitis virus), KINRIX (Corynebacteriumdiphtheriae), and Pediarix (Corynebacterium diphtheriae)); and conjugatevaccines (e.g., Arabinomannan-tetanus toxoid conjugate (Mycobacteriumtuberculosis)), CCPS-P64kR (Neisseria meningitidis), COMVAX (Haemophilusinfluenzae), Menjugate (Neisseria meningitidis), Neisvac-C (Neisseriameningitidis), and PedvaxHIB (Haemophilus influenzae)).

In some embodiments, the present adjuvants (e.g. flagellin-based agentand an aluminum gel or salt) are combined in a vaccine targeting asubstance abuse. For example, in one embodiment, the present adjuvantsare used in vaccines against addition to fentanyl, heroin, morphine,opium, oxycodone, hydrocodone, ketamine, PCP, barbiturates,benzodiazepines, flunitrazepam, GHB, methaqualone, hashish, marijuana,LSD, mescaline, psilocybin, amphetamine, cocaine, MDMA, methamphetamine,methylphenidate, and nicotine (e.g. TA-CD (Celtic Pharma), thosedescribed in US Patent Publication No. 2013/0011432, the contents ofwhich are hereby incorporated by reference (e.g. using6-(2R,3S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carbonyloxy-hexanoic acid (GNC) or6-((2R,3S)-3-(benzoyloxy)-8-methyl-8-azabicyclo [3.2.1]octane-2-carboxamido)hexanoic acid) (GNE) as the antigen, and TA-NIC(Celtic Pharma)).

In some embodiments, the present adjuvants (e.g. flagellin-based agentand an aluminum gel or salt) and/or the present vaccines may compriseany one of the adjuvants or antigens annotated in the VIOLIN or Vaxjodatabases (as described in He et al. Nucleic Acids Research. 2014. 42(D1): D1124-D1132 and Xiang et al. Nucleic Acids Res. 2008 January; 36:D923-8, the contents of which are hereby incorporated by reference intheir entirety).

In various embodiments, the present adjuvants (e.g. flagellin-basedagent and an aluminum gel or salt) may be part of one or more cancervaccines and/or the antigens of one or more cancer vaccines may be theantigens of the present invention. Illustrative cancer vaccines includetherapeutic and preventative vaccines. For instance, cancer vaccinesinclude ONCOPHAGE (ANTIGENICS INC., approved in Russia in 2008 forkidney cancer), APC8015/Sipuleucel-T/PROVENGE (DENDREON, for, e.g.metastatic hormone-refractory prostate cancer), CANCERVAX (CANVAXIN),GENITOPE CORP (MYVAX personalized immunotherapy), and FAVRILLE INC(FAVID), preventive vaccines which attack the cancer-causing viruseshuman papillomavirus (e.g. CERVARIX (GSK) and GARDASIL (MERCK)),hepatitis A virus (e.g. CERVARIX (GSK) and GARDASIL (MERCK)), andhepatitis B virus (e.g. RECOMBIVAX HB (MERCK), ENGERIX-B (GSK), ELOVAC B(HUMAN BIOLOGICALS INSTITUTE), GENEVAC B (SERUM INSTITUTE), SHANVAC B,etc.

In various embodiments, the present adjuvants (e.g. flagellin-basedagent and an aluminum gel or salt) may be part of one or more allergenvaccines and/or the antigens of one or more allergen vaccines may be theantigens of the present invention. For instance, subcutaneousimmunotherapy (SCIT) allergen compositions and methods are applicable tothe present invention (e.g. “allergy shots”). For example, vaccinationsfor allergic rhinitis and conjunctivitis (e.g. pollen (includingragweed), dust mites, animal dander and airborne mold spores); allergicor extrinsic bronchial asthma (e.g. house dust mites, pollen, animaldander, mold (Cladosporium), latex); and insect venom hypersensitivity.Allergens include pollen (e.g. tree, grass, weed), pet dander (e.g. catpelt), dust mites, airborne molds, occupational aeroallergens, honey beevenom, yellow jacket venom, hornet venom, wasp venom, and fire antvenom.

In various embodiments, the antigens of the present vaccines may be theantigens of live and attenuated or killed or inactivated or toxoid or asubunit or conjugate vaccines. In various embodiments, the antigen ofthe present vaccines is an antigen of any of the vaccines describedherein. For example, in some embodiments, the present antigen is that ofone or more of the following vaccines: DTP (diphtheria-tetanus-pertussisvaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib(Haemophilus influenzae type b) conjugate vaccines, Pneumococcalconjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellowfever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, HumanPapillomavirus (HPV) vaccine, Anthrax vaccine, Bacillus Calmette-Guérin(Tb), and Rabies vaccine.

In various embodiments, the flagellin-based agent and antigen areadsorbed to the aluminum gel or salt. In some embodiments, theflagellin-based agent and aluminum gel or salt are mixed to form astable complex. In some embodiments, the flagellin-based agent andaluminum gel or salt are mixed in a ratio that is substantially below aloading capacity of the aluminum salt. In some embodiments, theflagellin-based agent and aluminum gel or salt are present in a ratiothat is substantially below a loading capacity of the aluminum salt. Invarious embodiments, the flagellin-based agent and aluminum gel or saltare mixed or present in a ratio (w/w) of about 1:500, or about 1:600, orabout 1:700, or about 1:800, or about 1:900, or about 1:1000, or about1:2000, or about 1:5000, or about 1:6000, or about 1:7000, or about1:8000, or about 1:9000, or about 1:10000. In some embodiments, theflagellin-based agent and aluminum gel or salt are mixed in a ratio(w/w) of about 1:500 or less. In some embodiments, the flagellin-basedagent and aluminum gel or salt are present in a ratio that issubstantially below a loading capacity of the aluminum salt even in thepresence of antigen.

The loading (or adsorption) capacity of the adjuvant (e.g. the aluminumgel or salt) can be measured using a variety of analytical methods. Ingeneral, it is done by comparing the protein content in the aqueousphase of the agent being loaded or adsorbed (e.g. flagellin-based agentand/or antigen solution) before and after adsorption onto the adjuvant.For instance, the Ramon flocculation test may be used (as is used todetermine the adsorption of diphtheria and tetanus toxoid). Further,loading can be measured using immunoprecipitation techniques (e.g.quantitative immunoelectrophoresis or single radial immunodiffusion) orspectrophotometric techniques (e.g. the BCA method) ELISA methods mayalso be used as can immunoelectrophoresis or HPLC. The aluminum contentin the final vaccine can be monitored using a number of knowntechniques, including spectrometric methods, such as for example atomicadsorption spectrometry.

In some embodiments, the amount of aluminum gel or salt in the vaccinesand/or adjuvants described herein is about 0.05 to about 1.0 mg/dose, orabout 0.125 to about 0.625 mg/dose. In some embodiments, the amount ofaluminum gel or salt in the vaccines and/or adjuvants described hereinis about 0.05, or about 0.10, or about 0.15, or about 0.20, or about0.25, or about 0.30, or about 0.35, or about 0.40, or about 0.45, orabout 0.50, or about 0.55, or about 0.60, or about 0.65, or about 0.70,or about 0.75, or about 0.80, or about 0.85, or about 0.90, or about0.95, or about 1.0 mg/dose.

In some embodiments, the amount of flagellin-based agent is about 0.03to about 5 μg/dose (e.g. about 0.03 μg/dose, about 0.1 μg/dose, about0.3 μg/dose, about 0.5 μg/dose about 1.0 μg/dose, about 1.5 μg/dose,about 2.0 μg/dose, about 2.5 μg/dose, about 3.0 μg/dose, about 4.0μg/dose, about 4.5 μg/dose, about 5.0 μg/dose). In various embodiments,the present compositions and methods comprise doses of flagellin-basedagent that are less than about 5 μg/dose, or less than 4 μg/dose, orless than 3 μg/dose, or less than 2 μg/dose, or less than 1 μg/dose, orless than 0.5 μg/dose. In some embodiments, the present compositions andmethods comprise low doses of flagellin-based agent.

In various embodiments, the present compositions and methods do notinvolve covalently attaching an antigen to the flagellin-based agenteither as a fusion protein or via chemical conjugation. In variousembodiments, the present compositions do not have either equimolar ratioof antigen to flagellin-based agent (as in a fusion) or severalmolecules of hapten per one molecule of flagellin-based agent (as inchemical conjugates). In various embodiments, the amount offlagellin-based agent in any of the present vaccines is less than theamount of antigen. In various embodiments, the amount of flagellin-basedagent in any of the present vaccines is less than the amount of antigen.In various embodiments, the amount of flagellin-based agent in any ofthe present vaccines is substantially less than the amount of antigen.In various embodiments, the amount of flagellin-based agent in any ofthe present vaccines is about 500-fold, or about 450-fold, or about400-fold, or about 350-fold, or about 325-fold, or about 300-fold, orabout 250-fold, or about 200-fold, or about 150-fold, or about 100-fold,or about 50-fold less than the amount of antigen.

In various embodiments, the combination of flagellin-based agent andalum do not substantially effect TLR5 interaction by the flagellin-basedagent.

In various embodiments, the present compositions and methods do notinduce production of TNFα.

In various embodiments the present combination of flagellin-based agentand alum is substantially stable at low temperatures for about one week(e.g. at about 4° C. for about 3 days, or about 5 days, or about 6 days,or about 7 days, or about 10 days).

In another aspect, the present invention relates to a method ofvaccinating a subject against a disorder, comprising administering aneffective amount of a vaccine comprising an adjuvant comprising aflagellin-based agent and an aluminum gel or salt and an antigenassociated with the disorder. In another aspect, the invention relatesto a use of vaccine comprising an adjuvant comprising a flagellin-basedagent and an aluminum gel or salt and an antigen associated with adisorder for vaccinating a subject against the disorder. In anotheraspect, the invention relates to a use of an effective amount of vaccinecomprising an adjuvant comprising a flagellin-based agent and analuminum gel or salt and an antigen associated with a disorder in themanufacture of a medicament for vaccinating a subject against thedisorder.

In another aspect, the present invention relates to a method ofimmunostimulating a subject in advance of or concurrent withvaccination, comprising administering an effective amount of an adjuvantcomprising a flagellin-based agent and an aluminum gel or salt, whereinboth T_(H1) and T_(H2)-mediated immune responses are immunostimulated.In another aspect, the invention relates to a use of an effective amountof an adjuvant comprising a flagellin-based agent and an aluminum gel orsalt for immunostimulating a subject in advance of or concurrent withvaccination. In another aspect, the invention relates to a use of aneffective amount of an adjuvant comprising a flagellin-based agent andan aluminum gel or salt in the manufacture of a medicament forimmunostimulating a subject in advance of or concurrent withvaccination.

In various embodiments, the vaccine described herein causes animprovement in adjuvant properties relative to a vaccine comprising theantigen and the aluminum gel or salt alone (or flagellin-based agent andantigen alone). In various embodiments, the vaccine and/or adjuvantdescribed herein causes a broader, more diverse, more robust and longerlasting immunostimulatory effect than the vaccine comprising the antigenand the aluminum gel or salt alone (or flagellin-based agent and antigenalone) and/or the adjuvant comprising the aluminum gel or salt alone (orthe adjuvant comprising the flagellin-based agent alone).

In some embodiments, the described vaccine and/or described adjuvantcauses an increase in titer of 1 or more of, or 2 or more of, or 3 ormore of, or all of IgG1, IgG2a, IgG2b, and IgG3 antibodies (e.g.relative to the adjuvant comprising the aluminum gel or salt orflagellin-based agent alone, or relative to the vaccine comprising theantigen and the aluminum gel or salt alone or flagellin-based agentalone)). In some embodiments, the described vaccine and/or describedadjuvant causes a relative increase in the titer of all of IgG1, IgG2a,IgG2b, and IgG3 antibodies. In some embodiments, the described vaccineand/or described adjuvant causes a relative increase in the titer ofmore IgG3 antibodies than the described vaccine and/or describedadjuvant in the absence of a flagellin-based agent (or the describedvaccine and/or described adjuvant in the absence of an aluminum gel orsalt alone).

In some embodiments, the antigen is administered simultaneously with orsequentially to the adjuvant.

In some embodiments, the disorder is selected from infectious diseases,cancer, allergy, and autoimmune diseases.

In some embodiments, the disorder is selected from diphtheria, tetanus,pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellowfever, Human Papillomavirus (HPV) infection, anthrax, rabies, JapaneseEncephalitis, meningitis, measles, mumps, rubella, gastroenteritis,smallpox, typhoid fever, varicella (chickenpox), rotavirus, andshingles.

In some embodiments, the disorder is a cancer is selected from, but notlimited to, a basal cell carcinoma, biliary tract cancer; bladdercancer; bone cancer; brain and central nervous system cancer; breastcancer; cancer of the peritoneum; cervical cancer; choriocarcinoma;colon and rectum cancer; connective tissue cancer; cancer of thedigestive system; endometrial cancer; esophageal cancer; eye cancer;cancer of the head and neck; gastric cancer (including gastrointestinalcancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelialneoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer;lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer,adenocarcinoma of the lung, and squamous carcinoma of the lung);melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue,mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer;retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of therespiratory system; salivary gland carcinoma; sarcoma; skin cancer;squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer;uterine or endometrial cancer; cancer of the urinary system; vulvalcancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as wellas B-cell lymphoma (including low grade/follicular non-Hodgkin'slymphoma (NHL); small lymphocytic (SL) NHL; intermediategrade/follicular NHL; intermediate grade diffuse NHL; high gradeimmunoblastic NHL; high grade lymphoblastic NHL; high grade smallnon-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma;AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chroniclymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairycell leukemia; chronic myeloblastic leukemia; as well as othercarcinomas and sarcomas; and post-transplant lymphoproliferativedisorder (PTLD), as well as abnormal vascular proliferation associatedwith phakomatoses, edema (such as that associated with brain tumors),and Meigs' syndrome.

In some embodiments, the disorder is an allergy, selected from, by wayof non-limiting example, allergic rhinitis and conjunctivitis, allergicor extrinsic bronchial asthma, and insect venom hypersensitivity.

In some embodiments, the disorder is a substance abuse disorder (e.g. offentanyl, heroin, morphine, opium, oxycodone, hydrocodone, ketamine,PCP, barbiturates, benzodiazepines, flunitrazepam, GHB, methaqualone,hashish, marijuana, LSD, mescaline, psilocybin, amphetamine, cocaine,MDMA, methamphetamine, methylphenidate, and nicotine).

In some embodiments, the compositions of the present invention (e.g. thedescribed adjuvants and vaccines) can possess a sufficiently basicfunctional group, which can react with an inorganic or organic acid, ora carboxyl group, which can react with an inorganic or organic base, toform a pharmaceutically acceptable salt. A pharmaceutically acceptableacid addition salt is formed from a pharmaceutically acceptable acid, asis well known in the art. Such salts include the pharmaceuticallyacceptable salts listed in, for example, Journal of PharmaceuticalScience, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts;Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.),Verlag, Zurich (Switzerland) 2002, which are hereby incorporated byreference in their entirety.

Pharmaceutically acceptable salts include, by way of non-limitingexample, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide,nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate,salicylate, acid citrate, tartrate, oleate, tannate, pantothenate,bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate,gluconate, glucaronate, saccharate, formate, benzoate, glutamate,methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate,camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate,chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate,methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate,phenylbutyrate, α-hydroxybutyrate, butyne-1,4-dicarboxylate,hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, glycollate,heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate,mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate,phenylpropionate, sebacate, suberate, p-bromobenzenesulfonate,chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate,methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,naphthalene-1,5-sulfonate, xylenesulfonate, and tartarate salts.

The term “pharmaceutically acceptable salt” also refers to a salt of thecompositions of the present invention having an acidic functional group,such as a carboxylic acid functional group, and a base. Suitable basesinclude, but are not limited to, hydroxides of alkali metals such assodium, potassium, and lithium; hydroxides of alkaline earth metal suchas calcium and magnesium; hydroxides of other metals, such as aluminumand zinc; ammonia, and organic amines, such as unsubstituted orhydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine;tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine;triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such asmono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine,or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-loweralkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine ortri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such asarginine, lysine, and the like.

In some embodiments, the compositions of the present invention (e.g. thedescribed adjuvants and vaccines) described herein are in the form of apharmaceutically acceptable salt.

In some embodiments, the compositions of the present invention (e.g. thedescribed adjuvants and vaccines) may comprise a pharmaceuticallyacceptable carrier or vehicle. Such compositions can optionally comprisea suitable amount of a pharmaceutically acceptable excipient so as toprovide the form for proper administration.

Pharmaceutical excipients can be liquids, such as water and oils,including those of petroleum, animal, vegetable, or synthetic origin,such as peanut oil, soybean oil, mineral oil, sesame oil and the like.The pharmaceutical excipients can be, for example, saline, gum acacia,gelatin, starch paste, talc, keratin, colloidal silica, urea and thelike. In addition, auxiliary, stabilizing, thickening, lubricating, andcoloring agents can be used. In one embodiment, the pharmaceuticallyacceptable excipients are sterile when administered to a subject. Wateris a useful excipient when any agent described herein is administeredintravenously. Saline solutions and aqueous dextrose and glycerolsolutions can also be employed as liquid excipients, specifically forinjectable solutions. Suitable pharmaceutical excipients also includestarch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk,silica gel, sodium stearate, glycerol monostearate, talc, sodiumchloride, dried skim milk, glycerol, propylene, glycol, water, ethanoland the like. Any composition described herein, if desired, can alsocomprise minor amounts of wetting or emulsifying agents, or pH bufferingagents.

The present invention includes the compositions of the present invention(e.g. the described adjuvants and vaccines) in various formulations. Anycomposition of the present invention can take the form of solutions,suspensions, emulsion, drops, tablets, pills, pellets, capsules,capsules containing liquids, powders, sustained-release formulations,suppositories, emulsions, aerosols, sprays, suspensions, or any otherform suitable for use. In one embodiment, the composition is in the formof a capsule (see, e.g., U.S. Pat. No. 5,698,155). Other examples ofsuitable pharmaceutical excipients are described in Remington'sPharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed.1995), incorporated herein by reference.

Where necessary, the compositions of the present invention can alsoinclude a solubilizing agent. Also, the agents can be delivered with asuitable vehicle or delivery device as known in the art. Combinationtherapies outlined herein can be co-delivered in a single deliveryvehicle or delivery device. Compositions for administration canoptionally include a local anesthetic such as, for example, lignocaineto lessen pain at the site of the injection.

The formulations comprising the compositions of the present inventionmay conveniently be presented in unit dosage forms and may be preparedby any of the methods well known in the art of pharmacy. Such methodsgenerally include the step of bringing the therapeutic agents intoassociation with a carrier, which constitutes one or more accessoryingredients. Typically, the formulations are prepared by uniformly andintimately bringing the therapeutic agent into association with a liquidcarrier, a finely divided solid carrier, or both, and then, ifnecessary, shaping the product into dosage forms of the desiredformulation (e.g., wet or dry granulation, powder blends, etc., followedby tableting using conventional methods known in the art).

In one embodiment, any composition of the present invention isformulated in accordance with routine procedures as a compositionadapted for a mode of administration described herein.

Routes of administration include intramuscular, e.g. by injection orinfusion. In some embodiments, the described adjuvant of aflagellin-based agent (e.g. CBLB502) and aluminum gel or salt mayprevent systemic delivery of the flagellin-based agent and inducelocalized delivery. In other embodiments, routes of administrationinclude nasal, oral, and sublingual delivery.

Routes of administration may also be intradermal, intramuscular,intraperitoneal, intravenous, subcutaneous, intranasal, oral,sublingual, intranasal, transdermal, or by inhalation. In someembodiments, the administering is effected orally or by parenteralinjection. The mode of administration can be left to the discretion ofthe practitioner, and depends in-part upon the site of the medicalcondition. In most instances, administration results in the release ofany agent described herein into the bloodstream.

Any composition of the present invention (e.g. the described adjuvantsand vaccines) can be administered orally. Such compositions can also beadministered by any other convenient route, for example, by intravenousinfusion or bolus injection, by absorption through epithelial ormucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa,etc.) and can be administered together with another biologically activeagent. Administration can be systemic or local. Various delivery systemsare known, e.g., encapsulation in liposomes, microparticles,microcapsules, capsules, etc., and can be used to administer.

Dosage forms suitable for parenteral administration (e.g. intravenous,intramuscular, intraperitoneal, subcutaneous and intra-articularinjection and infusion) include, for example, solutions, suspensions,dispersions, emulsions, and the like. They may also be manufactured inthe form of sterile solid compositions (e.g. lyophilized composition),which can be dissolved or suspended in sterile injectable mediumimmediately before use. They may contain, for example, suspending ordispersing agents known in the art.

The dosage of any composition of the present invention (e.g. thedescribed adjuvants and vaccines) as well as the dosing schedule candepend on various parameters, including, but not limited to, thedisorder being treated, the subject's general health, and theadministering physician's discretion.

In vitro or in vivo assays can be employed to help identify optimaldosage ranges. For example, doses may be determined with referencePhysicians' Desk Reference, 66th Edition, PDR Network; 2012 Edition(Dec. 27, 2011), the contents of which are incorporated by reference inits entirety.

For administration of a composition of the present invention (e.g. thedescribed adjuvants and vaccines) by parenteral injection, the dosage isnormally about 0.1 mg to about 250 mg per day, about 1 mg to about 20 mgper day, or about 3 mg to about 5 mg per day. Injections may be given upto four times daily. Generally, when orally or parenterallyadministered, the dosage of any agent described herein is normally about0.1 mg to about 1500 mg per day, or about 0.5 mg to about 10 mg per day,or about 0.5 mg to about 5 mg per day. A dosage of up to about 3000 mgper day can be administered.

In another embodiment, delivery can be in a vesicle, in particular aliposome (see Langer, 1990, Science 249:1527-1533; Treat et al., inLiposomes in the Therapy of Infectious Disease and Cancer,Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989).

Any composition of the present invention (e.g. the described adjuvantsand vaccines) can be administered by controlled-release orsustained-release means or by delivery devices that are well known tothose of ordinary skill in the art. Examples include, but are notlimited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899;3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767;5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of whichis incorporated herein by reference in its entirety. Such dosage formscan be useful for providing controlled- or sustained-release of one ormore active ingredients using, for example, hydropropylmethyl cellulose,other polymer matrices, gels, permeable membranes, osmotic systems,multilayer coatings, microparticles, liposomes, microspheres, or acombination thereof to provide the desired release profile in varyingproportions. Suitable controlled- or sustained-release formulationsknown to those skilled in the art, including those described herein, canbe readily selected for use with the active ingredients of the agentsdescribed herein. The invention thus provides single unit dosage formssuitable for oral administration such as, but not limited to, tablets,capsules, gelcaps, and caplets that are adapted for controlled- orsustained-release.

Controlled- or sustained-release of an active ingredient can bestimulated by various conditions, including but not limited to, changesin pH, changes in temperature, stimulation by an appropriate wavelengthof light, concentration or availability of enzymes, concentration oravailability of water, or other physiological conditions or compounds.

In another embodiment, polymeric materials can be used (see MedicalApplications of Controlled Release, Langer and Wise (eds.), CRC Pres.,Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug ProductDesign and Performance, Smolen and Ball (eds.), Wiley, New York (1984);Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61;see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann.Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).

In another embodiment, a controlled-release system can be placed inproximity of the target area to be treated, thus requiring only afraction of the systemic dose (see, e.g., Goodson, in MedicalApplications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).Other controlled-release systems discussed in the review by Langer,1990, Science 249:1527-1533) may be used.

Administration of a composition of the present invention (e.g. thedescribed adjuvants and vaccines) can, independently, be once perpatient or may be used in a booster strategy. Administration may beabout one to about four times daily or about one to about four times permonth or about one to about six times per year or once every two, three,four or five years. Administration can be for the duration of about oneday or about one month, about two months, about three months, about sixmonths, about one year, about two years, about three years, and may evenbe for the life of the subject. The dosage may be administered as asingle dose or divided into multiple doses.

The dosage regimen utilizing any flagellin related composition (and/oradditional agents) described herein can be selected in accordance with avariety of factors including type, species, age, weight, sex and medicalcondition of the subject; the severity of the condition to be treated;the route of administration; the renal or hepatic function of thesubject; the pharmacogenomic makeup of the individual; and the specificcompound of the invention employed. Any flagellin related composition(and/or additional agents) described herein can be administered in asingle daily dose, or the total daily dosage can be administered individed doses of two, three or four times daily. Furthermore, anyflagellin related composition (and/or additional agents) describedherein can be administered continuously rather than intermittentlythroughout the dosage regimen.

In some embodiments, the composition of the present invention (e.g. thedescribed adjuvants and vaccines) may be used in conjunction with one ormore additional agents. In some embodiments, the invention pertains toco-administration and/or co-formulation. Any of the compositionsdescribed herein may be co-formulated and/or co-administered.

In some embodiments, any composition described herein actssynergistically when co-administered with another agent and isadministered at doses that are lower than the doses commonly employedwhen such agents are used as monotherapy. In various embodiments, anyagent referenced herein may be used in combination with any of thecomposition described herein.

In some embodiments, the present invention pertains to additional agentsdescribed elsewhere herein. In one embodiment, any flagellin-relatedagent or composition comprising the same may be used with agents thatstimulate NOD receptors (e.g. NOD1 and NOD2 agonists, such aspeptidoglycan, C12-iE-DAP and L18-MDP) and as described in Infect Immun.October 2013; 81(10): 3855-3864, the contents of which are herebyincorporated by reference in their entirety.

In some embodiments, the present invention pertains to chemotherapeuticagents as additional agents.

Examples of chemotherapeutic agents include, but are not limited to,alkylating agents such as thiotepa and CYTOXAN cyclosphosphamide; alkylsulfonates such as busulfan, improsulfan and piposulfan; aziridines suchas benzodopa, carboquone, meturedopa, and uredopa; ethylenimines andmethylamelamines including altretamine, triethylenemelamine,trietylenephosphoramide, triethiylenethiophosphoramide andtrimethylolomelamine; acetogenins (e.g., bullatacin and bullatacinone);a camptothecin (including the synthetic analogue topotecan); bryostatin;cally statin; CC-1065 (including its adozelesin, carzelesin andbizelesin synthetic analogues); cryptophycins (e.g., cryptophycin 1 andcryptophycin 8); dolastatin; duocarmycin (including the syntheticanalogues, KW-2189 and CB 1-TM1); eleutherobin; pancratistatin; asarcodictyin; spongistatin; nitrogen mustards such as chlorambucil,chlornaphazine, cholophosphamide, estramustine, ifosfamide,mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard;nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine,nimustine, and ranimnustine; antibiotics such as the enediyneantibiotics (e.g., calicheamicin, especially calicheamicin gammaII andcalicheamicin omegaII (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33:183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, suchas clodronate; an esperamicin; as well as neocarzinostatin chromophoreand related chromoprotein enediyne antibiotic chromophores),aclacinomysins, actinomycin, authramycin, azaserine, bleomycins,cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis,dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine,ADRIAMYCIN doxorubicin (including morpholino-doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin,mitomycins such as mitomycin C, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; def of amine;demecolcine; diaziquone; elformithine; elliptinium acetate; anepothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;lonidainine; maytansinoids such as maytansine and ansamitocins;mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin;phenamet; pirarubicin; losoxantrone; podophyllinic acid;2-ethylhydrazide; procarbazine; PSK polysaccharide complex (JHS NaturalProducts, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium;tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine;trichothecenes (e.g., T-2 toxin, verracurin A, roridin A and anguidine);urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol;pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide;thiotepa; taxoids, e.g., TAXOL paclitaxel (Bristol-Myers SquibbOncology, Princeton, N.J.), ABRAXANE Cremophor-free, albumin-engineerednanoparticle formulation of paclitaxel (American PharmaceuticalPartners, Schaumberg, 111), and TAXOTERE doxetaxel (Rhone-Poulenc Rorer,Antony, France); chloranbucil; GEMZAR gemcitabine; 6-thioguanine;mercaptopurine; methotrexate; platinum analogs such as cisplatin,oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16);ifosfamide; mitoxantrone; vincristine; NAVELBINE. vinorelbine;novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda;ibandronate; irinotecan (Camptosar, CPT-11) (including the treatmentregimen of irinotecan with 5-FU and leucovorin); topoisomerase inhibitorRFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoicacid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin,including the oxaliplatin treatment regimen (FOLFOX); lapatinib(Tykerb); inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g., erlotinib(Tarceva)) and VEGF-A that reduce cell proliferation andpharmaceutically acceptable salts, acids or derivatives of any of theabove. In addition, the methods of treatment can further include the useof radiation. In addition, the methods of treatment can further includethe use of photodynamic therapy.

In some embodiments, the flagellin-based agents (and/or additionalagents) described herein, include derivatives that are modified, i.e.,by the covalent attachment of any type of molecule to the compositionsuch that covalent attachment does not prevent the activity of thecomposition. For example, but not by way of limitation, derivativesinclude composition that have been modified by, inter alia,glycosylation, lipidation, acetylation, pegylation, phosphorylation,amidation, derivatization by known protecting/blocking groups,proteolytic cleavage, linkage to a cellular ligand or other protein,etc. Any of numerous chemical modifications can be carried out by knowntechniques, including, but not limited to specific chemical cleavage,acetylation, formylation, metabolic synthesis of turicamycin, etc.Additionally, the derivative can contain one or more non-classical aminoacids.

In still other embodiments, the flagellin-based agents (and/oradditional agents) described herein further comprise a cytotoxic agent,comprising, in illustrative embodiments, a toxin, a chemotherapeuticagent, a radioisotope, and an agent that causes apoptosis or cell death.Such agents may be conjugated to a composition described herein.

The flagellin-based agents (and/or additional agents) described hereinmay thus be modified post-translationally to add effector moieties suchas chemical linkers, detectable moieties such as for example fluorescentdyes, enzymes, substrates, bioluminescent materials, radioactivematerials, and chemiluminescent moieties, or functional moieties such asfor example streptavidin, avidin, biotin, a cytotoxin, a cytotoxicagent, and radioactive materials.

Illustrative cytotoxic agents include, but are not limited to,methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine,5-fluorouracil decarbazine; alkylating agents such as mechlorethamine,thioepa chlorambucil, melphalan, carmustine (BSNU), mitomycin C,lomustine (CCNU), 1-methylnitrosourea, cyclothosphamide,mechlorethamine, busulfan, dibromomannitol, streptozotocin, mitomycin C,cis-dichlorodiamine platinum (II) (DDP) cisplatin and carboplatin(paraplatin); anthracyclines include daunorubicin (formerly daunomycin),doxorubicin (adriamycin), detorubicin, carminomycin, idarubicin,epirubicin, mitoxantrone and bisantrene; antibiotics includedactinomycin (actinomycin D), bleomycin, calicheamicin, mithramycin, andanthramycin (AMC); and antimytotic agents such as the vinca alkaloids,vincristine and vinblastine. Other cytotoxic agents include paclitaxel(taxol), ricin, Pseudomonas exotoxin, gemcitabine, cytochalasin B,gramicidin D, ethidium bromide, emetine, etoposide, tenoposide,colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone,glucocorticoids, procaine, tetracaine, lidocaine, propranolol,puromycin, procarbazine, hydroxyurea, asparaginase, corticosteroids,mytotane (O,P′-(DDD)), interferons, and mixtures of these cytotoxicagents.

Further cytotoxic agents include, but are not limited to,chemotherapeutic agents such as carboplatin, cisplatin, paclitaxel,gemcitabine, calicheamicin, doxorubicin, 5-fluorouracil, mitomycin C,actinomycin D, cyclophosphamide, vincristine, bleomycin, VEGFantagonists, EGFR antagonists, platins, taxols, irinotecan,5-fluorouracil, gemcytabine, leucovorine, steroids, cyclophosphamide,melphalan, vinca alkaloids (e.g., vinblastine, vincristine, vindesineand vinorelbine), mustines, tyrosine kinase inhibitors, radiotherapy,sex hormone antagonists, selective androgen receptor modulators,selective estrogen receptor modulators, PDGF antagonists, TNFantagonists, IL-1 antagonists, interleukins (e.g. IL-12 or IL-2), IL-12Rantagonists, Toxin conjugated monoclonal antibodies, tumor antigenspecific monoclonal antibodies, Erbitux, Avastin, Pertuzumab, anti-CD20antibodies, Rituxan, ocrelizumab, ofatumumab, DXL625, HERCEPTIN®, or anycombination thereof. Toxic enzymes from plants and bacteria such asricin, diphtheria toxin and Pseudomonas toxin may be conjugated to thetherapeutic agents (e.g. antibodies) to generatecell-type-specific-killing reagents (Youle, et al., Proc. Nat'l Acad.Sci. USA 77:5483 (1980); Gilliland, et al., Proc. Nat'l Acad. Sci. USA77:4539 (1980); Krolick, et al., Proc. Nat'l Acad. Sci. USA 77:5419(1980)).

Other cytotoxic agents include cytotoxic ribonucleases as described byGoldenberg in U.S. Pat. No. 6,653,104. Embodiments of the invention alsorelate to radioimmunoconjugates where a radionuclide that emits alpha orbeta particles is stably coupled to the antibody, or binding fragmentsthereof, with or without the use of a complex-forming agent. Suchradionuclides include beta-emitters such as Phosphorus-32, Scandium-47,Copper-67, Gallium-67, Yttrium-88, Yttrium-90, Iodine-125, Iodine-131,Samarium-153, Lutetium-177, Rhenium-186 or Rhenium-188, andalpha-emitters such as Astatine-211, Lead-212, Bismuth-212, Bismuth-213or Actinium-225.

Illustrative detectable moieties further include, but are not limitedto, horseradish peroxidase, acetylcholinesterase, alkaline phosphatase,beta-galactosidase and luciferase. Further illustrative fluorescentmaterials include, but are not limited to, rhodamine, fluorescein,fluorescein isothiocyanate, umbelliferone, dichlorotriazinylamine,phycoerythrin and dansyl chloride. Further illustrative chemiluminescentmoieties include, but are not limited to, luminol. Further illustrativebioluminescent materials include, but are not limited to, luciferin andaequorin. Further illustrative radioactive materials include, but arenot limited to, Iodine-125, Carbon-14, Sulfur-35, Tritium andPhosphorus-32.

In some embodiments, the subject and/or animal is a mammal, e.g., ahuman, mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep,or non-human primate, such as a monkey, chimpanzee, or baboon. In otherembodiments, the subject and/or animal is a non-mammal, such, forexample, a zebrafish. In some embodiments, the subject and/or animal maycomprise fluorescently-tagged cells (with e.g. GFP). In someembodiments, the subject and/or animal is a transgenic animal comprisinga fluorescent cell.

In some embodiments, the subject and/or animal is a human. In someembodiments, the human is a pediatric human. In other embodiments, thehuman is an adult human. In other embodiments, the human is a geriatrichuman. In other embodiments, the human may be referred to as a patient.

In certain embodiments, the human has an age in a range of from about 0months to about 6 months old, from about 6 to about 12 months old, fromabout 6 to about 18 months old, from about 18 to about 36 months old,from about 1 to about 5 years old, from about 5 to about 10 years old,from about 10 to about 15 years old, from about 15 to about 20 yearsold, from about 20 to about 25 years old, from about 25 to about 30years old, from about 30 to about 35 years old, from about 35 to about40 years old, from about 40 to about 45 years old, from about 45 toabout 50 years old, from about 50 to about 55 years old, from about 55to about 60 years old, from about 60 to about 65 years old, from about65 to about 70 years old, from about 70 to about 75 years old, fromabout 75 to about 80 years old, from about 80 to about 85 years old,from about 85 to about 90 years old, from about 90 to about 95 years oldor from about 95 to about 100 years old.

In other embodiments, the subject is a non-human animal, and thereforethe invention pertains to veterinary use. In a specific embodiment, thenon-human animal is a household pet. In another specific embodiment, thenon-human animal is a livestock animal.

The invention provides kits that can simplify the administration of anyagent described herein. An illustrative kit of the invention comprisesany composition described herein in unit dosage form. In one embodiment,the unit dosage form is a container, such as a pre-filled syringe, whichcan be sterile, containing any agent described herein and apharmaceutically acceptable carrier, diluent, excipient, or vehicle. Thekit can further comprise a label or printed instructions instructing theuse of any agent described herein. The kit may also include a lidspeculum, topical anesthetic, and a cleaning agent for theadministration location. The kit can also further comprise one or moreadditional agent described herein. In one embodiment, the kit comprisesa container containing an effective amount of a composition of theinvention and an effective amount of another composition, such thosedescribed herein.

The following definitions are used in connection with the inventiondisclosed herein. Unless defined otherwise, all technical and scientificterms used herein have the same meaning as commonly understood to one ofskill in the art to which this invention belongs.

As used herein, “a,” “an,” or “the” can mean one or more than one.

Further, the term “about” when used in connection with a referencednumeric indication means the referenced numeric indication plus or minusup to 10% of that referenced numeric indication. For example, thelanguage “about 50” covers the range of 45 to 55.

An “effective amount,” when used in connection with medical uses is anamount that is effective for providing a measurable treatment,prevention, or reduction in the rate of pathogenesis of a disease ofinterest.

As used herein, something is “decreased” if a read-out of activityand/or effect is reduced by a significant amount, such as by at leastabout 10%, at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, at least about 95%, at least about 97%,at least about 98%, or more, up to and including at least about 100%, inthe presence of an agent or stimulus relative to the absence of suchmodulation. As will be understood by one of ordinary skill in the art,in some embodiments, activity is decreased and some downstream read-outswill decrease but others can increase.

Conversely, activity is “increased” if a read-out of activity and/oreffect is increased by a significant amount, for example by at leastabout 10%, at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, at least about 95%, at least about 97%,at least about 98%, or more, up to and including at least about 100% ormore, at least about 2-fold, at least about 3-fold, at least about4-fold, at least about 5-fold, at least about 6-fold, at least about7-fold, at least about 8-fold, at least about 9-fold, at least about10-fold, at least about 50-fold, at least about 100-fold, in thepresence of an agent or stimulus, relative to the absence of such agentor stimulus.

As referred to herein, all compositional percentages are by weight ofthe total composition, unless otherwise specified. As used herein, theword “include,” and its variants, is intended to be non-limiting, suchthat recitation of items in a list is not to the exclusion of other likeitems that may also be useful in the compositions and methods of thistechnology. Similarly, the terms “can” and “may” and their variants areintended to be non-limiting, such that recitation that an embodiment canor may comprise certain elements or features does not exclude otherembodiments of the present technology that do not contain those elementsor features.

Although the open-ended term “comprising,” as a synonym of terms such asincluding, containing, or having, is used herein to describe and claimthe invention, the present invention, or embodiments thereof, mayalternatively be described using alternative terms such as “consistingof” or “consisting essentially of.”

As used herein, the words “preferred” and “preferably” refer toembodiments of the technology that afford certain benefits, undercertain circumstances. However, other embodiments may also be preferred,under the same or other circumstances. Furthermore, the recitation ofone or more preferred embodiments does not imply that other embodimentsare not useful, and is not intended to exclude other embodiments fromthe scope of the technology.

The amount of compositions described herein needed for achieving atherapeutic effect may be determined empirically in accordance withconventional procedures for the particular purpose. Generally, foradministering therapeutic agents (e.g. flagellin-based agents,flagellin-based agents (and/or additional agents) described herein) fortherapeutic purposes, the therapeutic agents are given at apharmacologically effective dose. A “pharmacologically effectiveamount,” “pharmacologically effective dose,” “therapeutically effectiveamount,” or “effective amount” refers to an amount sufficient to producethe desired physiological effect or amount capable of achieving thedesired result, particularly for treating the disorder or disease. Aneffective amount as used herein would include an amount sufficient to,for example, delay the development of a symptom of the disorder ordisease, alter the course of a symptom of the disorder or disease (e.g.,slow the progression of a symptom of the disease), reduce or eliminateone or more symptoms or manifestations of the disorder or disease, andreverse a symptom of a disorder or disease. For example, administrationof therapeutic agents to a patient suffering from cancer provides atherapeutic benefit not only when the underlying condition is eradicatedor ameliorated, but also when the patient reports a decrease in theseverity or duration of the symptoms associated with the disease, e.g.,a decrease in tumor burden, a decrease in circulating tumor cells, anincrease in progression free survival. Therapeutic benefit also includeshalting or slowing the progression of the underlying disease ordisorder, regardless of whether improvement is realized.

Effective amounts, toxicity, and therapeutic efficacy can be determinedby standard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., for determining the LD50 (the dose lethal to about 50% ofthe population) and the ED50 (the dose therapeutically effective inabout 50% of the population). The dosage can vary depending upon thedosage form employed and the route of administration utilized. The doseratio between toxic and therapeutic effects is the therapeutic index andcan be expressed as the ratio LD50/ED50. In some embodiments,compositions and methods that exhibit large therapeutic indices arepreferred. A therapeutically effective dose can be estimated initiallyfrom in vitro assays, including, for example, cell culture assays. Also,a dose can be formulated in animal models to achieve a circulatingplasma concentration range that includes the IC50 as determined in cellculture, or in an appropriate animal model. Levels of the describedcompositions in plasma can be measured, for example, by high performanceliquid chromatography. The effects of any particular dosage can bemonitored by a suitable bioassay. The dosage can be determined by aphysician and adjusted, as necessary, to suit observed effects of thetreatment.

In certain embodiments, the effect will result in a quantifiable changeof at least about 10%, at least about 20%, at least about 30%, at leastabout 50%, at least about 70%, or at least about 90%. In someembodiments, the effect will result in a quantifiable change of about10%, about 20%, about 30%, about 50%, about 70%, or even about 90% ormore. Therapeutic benefit also includes halting or slowing theprogression of the underlying disease or disorder, regardless of whetherimprovement is realized.

In certain embodiments, a pharmacologically effective amount that willtreat cancer will modulate the symptoms typically by at least about 10%,at least about 20%, at least about 30%, at least about 40%, or at leastabout 50%. In illustrative embodiments, such modulations will result in,for example, statistically significant and quantifiable changes in thenumbers of cancerous cells.

This invention is further illustrated by the following non-limitingexamples.

EXAMPLES Example 1: Preparation of the Model Vaccine

Alum adjuvant (IMJECT ALUM, THERMO) was used in combination with CBLB502to challenge the mice with a model antigen, ovalbumin (OVA). Vaccine wascomprised of the following components as shown in TABLE A:

Amount Component (per mouse) Ovalbumin 10 mg CBLB502 1 ug/10 ug AlumAdjuvant 500 ug

To achieve excellent absorption CBLB502 (either 1 ug or 10 ug) was mixedwith 10 mg of OVA and 500 μg of Alum adjuvant for 30 minutes at 300 rpmat room temperature.

Example 2: Mouse Immunization Study

C57Bl/6 male mice (10 weeks of age, n=6 for each experiment) were usedfor injection. Mice were divided into five groups with six animals ineach group (n=6). Mice were injected with 100 μl of above describedvaccine in each of the hind legs (200 μl total per mouse) as shown inTABLE B.

Ovalbumin CBLB502 Alum Adjuvant Group 1 Group 2 10 mg Group 3 10 mg 500ug Group 4 10 mg  1 ug 500 ug Group 5 10 mg 10 ug 500 ug

Two weeks after the initial immunization mice were challenged with anadditional booster following the same setup as the original injection.Plasma was collected one, two and four weeks after booster viamandibular vein. Using an ELISA based assay total IgG, IgG1, IgG2a,IgG2b and IgG3 were measured. Results are shown in FIGS. 2-3. In thefigures, Group 1 is also called “Untreated;” Group 2 is also called“OVA,” Groups 3 is also called “OVA+Alum,” Group 4 is also called “SA 1μg,” and Group 5 is also called “SA 10 μg.”

FIG. 2 shows ELISA data for the average response of the fiveaforementioned mouse treatment groups at the time point of 1 weekpost-boost. FIG. 3 shows ELISA data for the average response of the fiveaforementioned mouse treatment groups at the time point of 2 weekspost-boost. FIG. 4 shows ELISA data for the average response of the fiveaforementioned mouse treatment groups at the time point of 4 weekspost-boost.

Example 3: Evaluation of CBLB502 Binding to ALHYDROGEL

The binding capacity of ALHYDROGEL for CBLB502 was evaluated. ALHYDROGELadjuvant 2%, aluminium hydroxide wet gel (colloidal) suspension(INVIVIGEN Catalog #vac-alu-250), was mixed with CBLB502 at differentvolume ratios, resulting in 10 to 52% ALHYDROGEL suspension in thereaction. CBLB502 concentration was maintained at 10 μg/ml,corresponding to a 1 μg/100 μl inoculation dose (100 μl inoculationvolume is the recommended maximum volume for subcutaneous injection ofantigen/adjuvant mixtures per injection site for mice). After overnightincubation at 4° C., the tubes were centrifuged to sediment ALHYDROGELand unbound CBLB502, remaining in solution was measured by ELISA. Theamounts of adsorbed CBLB502 were calculated as difference between totalprotein added to the mixture and unbound CBLB502 (TABLE C). The maximumadsorption of CBLB502, more than 99.9% bound, was observed when thereactions were formulated with 40 to 52 μl ALHYDROGEl/100 μl; at lowerratios, the binding efficiency decreased gradually to about 83% at 10μl/100 μl ALHYDROGEL suspension.

TABLE C CBLB502 adsorption at different ALHYDROGEL 2% volume ratios. Thebinding reactions were composed of CBLB502, PBS and the indicatedvolumes of ALHYDROGEl adjuvant 2%. ALHYDROGEL 2% CBLB502 dose TotalCBLB502 Unbound Bound Bound μl/100 μl μg/100 μl ng/ml ng/ml ng/ml (%) 152 1 10000 2.1 9997.9 99.98 2 50 1 10000 1.6 9998.4 99.98 3 40 1 100002.9 9997.1 99.97 4 30 1 10000 22.7 9977.3 99.77 5 20 1 10000 173.49826.6 98.27 6 10 1 10000 1692.5 8307.5 83.07

CBLB502 binding to ALHYDROGEL was also evaluated at different CBLB502doses. Adsorption of CBLB502 to ALHYDROGEL (52 μl/100 μl ALHYDROGELadjuvant 2%) was determined at CBLB502 doses, ranging from approximately0.02 to 20 μg per 100 μl. The reactions were incubated as describedabove and unbound CBLB502 was measured by ELISA. The results (TABLE D)demonstrated that almost complete binding of the drug to ALHYDROGEL,99.82 to 99.99% bound, was accomplished at all tested CBLB502concentrations.

TABLE D Efficiency of CBLB502 binding to ALHYDROGEL in PBS. Theincubations were performed with CBLB502 at the indicated doses in PBSand 52 μ1/100 μl ALHYDROGEL adjuvant 2%. CBLB502 dose Total CBLB502Unbound Bound Bound μg/100 μ1 ng/ml ng/ml ng/ml (%) 1 20 200000 199.3199800.7 99.90 2 5 50000 90.6 49909.4 99.82 3 1.25 12500 0.79 12499.299.99 4 0.31 3125.0 0.029 3124.97 99.99 5 0.078 781.25 0.023 781.2399.99 6 0.02 195.31 0.011 195.30 99.99

CBLB502 binding to ALHYDROGEL in the presence of TT-SMA vaccine wasevaluated. Binding efficiency of CBLB502 to ALHYDROGEL was tested in thepresence of a vaccine candidate TT-SMA, succinyl methamphetamine (SMA)hapten conjugated to tetanus toxoid. In a separate study, shown below,this vaccine was administered to mice at a 32 μg/100 μl dose to compareefficacy with and without CBLB502. This TT-SMA dose was co-incubatedwith CBLB502 (0.02 to 20 μg/100 μl) and ALHYDROGEL (52 μl/100 μl) understandard conditions and unbound CBLB502 was measured by ELISA. Thebinding efficiency was 99.7 to 99.9% at all tested CBLB502concentrations, indicating that CBLB502 adsorption to ALHYDROGEL wasunaffected with addition of TT-SMA to the reaction mixture

TABLE E CBLB502 binding to ALHYDROGEL in the presence of TT-SMA. Theincubations were performed with CBLB502 at the indicated doses in PBS,52 μl/100 μl ALHYDROGEL adjuvant 2% and 32 μg/100 μl TT-SMA conjugate.CBLB502 dose Total CBLB502 Unbound Bound Bound μg/100 μl ng/ml ng/mlng/ml (%) 1 20 200000 668.88 199331.1 99.67 2 5 50000 50.21 49949.899.90 3 1.25 12500 11.44 12488.6 99.91 4 0.31 3125.0 1.65 3123.4 99.95 50.078 781.25 0.13 781.1 99.98 6 0.02 195.31 0.06 195.2 99.96

Example 4: Analysis of In Vitro CBLB502 Activity after Adsorption toALHYDROGEL

An activity assay of CBLB502/ALHYDROGEL using 293-hTLR5-LacZ reportercells was undertaken. Biological activity of CBLB502 after adsorption toALHYDROGEL was tested using an in vitro assay which measures activationof a NF-κB-controlled reporter enzyme, β-galactosidase, inHEK293-hTLR5::NF-κB-lacZ (293-hTLR5-LacZ) cells. Since 293-hTLR5-LacZcells express only one cell membrane-bound toll-like receptor, humanTLR5, CBLB502 activity could be determined without interference fromother toll-like receptor ligands such as LPS (endotoxin).

Specific induction of the β-galactosidase reporter by CBLB502/ALHYDROGELwas demonstrated after incubating the cells with a serially dilutedCBLB502/ALHYDROGEL formulation (5 μg/100 μl), starting with a 2000-folddilution in cell growth media and resulting in the concentration rangeof ALHYDROGEL-adsorbed CBLB502 from 25 to 0.004 ng/ml (FIG. 5). Themaximum β-galactosidase activity was observed at 0.93 ng/mlALHYDROGEL-adsorbed CBLB502; this value was consistent with typicalresults of the assay using soluble CBLB502 where the reporter enzymeactivity would normally peak around 1 ng/ml. ALHYDROGEL alone tested atsame dilutions did not induce the reporter. Therefore, it could beconcluded, inter alia, that CBLB502 retains its biological activityafter adsorption to ALHYDROGEL and becomes readily available forinteraction with its target receptor (TLR5) under regular cell cultureconditions.

Next, CBLB502/ALHYDROGEL suspensions were prepared at CBLB502inoculation doses ranging from 2.5 to 0.00015 μg/100 μl and were addedto 293-hTLR5-LacZ cells at 200-fold dilution (FIG. 6). NF-κB-inducingactivity followed a typical dose-response pattern and was measured atsub-nanogram doses of CBLB502/ALHYDROGEL (less than 0.001 μg/100 μl),indicating that at such low doses, CBLB502 was not irreversibly bound tothe alum adjuvant and remained active.

An activity titration of CBLB502/ALHYDROGEL at different CBLB502 doseswas undertaken. CBLB502/ALHYDROGEL suspensions were titrated in cellculture media and incubated with 293-hTLR5-LacZ cells. CBLB502 standardswere included in the assay to compare the recovered activity. Theresulting reporter enzyme activity was plotted against theoreticalconcentrations of ALHYDROGEL-bound CBLB502, assuming that the proteinwas completely available (FIG. 7).

The results of titration assay demonstrated that at a formulation doseof 20 μg/100 μl, the activity of CBLB502 followed the expectedconcentrations, essentially matching the activity of soluble standards.However, reduction of the dose 64- and 256-fold to respectively, about0.31 and 0.078 μg/100 μl, resulted in lower relative recovery ofNF-κB-inducing activity to approximately 15-30%. This apparent loss ofCBLB502 activity could be due to stronger binding of the particularamounts of the protein relative to the amounts of alum in theformulation. These fixed amounts could represent a small fraction oftotal CBLB502 at the higher doses such as 20 μg/100 μl and would notaffect significantly the measured activity. However, at lower doses,this tightly adsorbed fraction may become substantial compared to thetotal protein, leading to a lower measurable activity of CBLB502

Example 5: Assessment of CBLB502/ALHYDROGEL Short-Term Storage Stabilityat 4° C.

A formulation of 1 μg/100 μl CBLB502 (52 μl/100 μl ALHYDROGEL 2%) wasprepared and tested for activity after 2 and 6 days storage at 4° C. Theresults of CBLB502 activity assay using 293-hTLR5-LacZ reporter cellsare shown in FIG. 8. Based on comparison with the soluble CBLB502standard, in can be concluded that NF-κB-inducing activity ofALHYDROGEL-adsorbed CBLB502 remained unchanged after 6 days under thestorage conditions.

Example 6: Evaluation of CBLB502 Dissociation from ALHYDROGEL in PBS andCell Media

Aliquots of CBLB502/ALHYDROGEL (1 μg/100 μl dose; 52 μl/100 μlALHYDROGEL 2%) were re-suspended in PBS or cell media (DMEM supplementedwith 10% FBS) and incubated for 3 hr at 22° C. and 37° C. Aftercentrifugation to remove ALHYDROGEL, dissociated CBLB502 was measured insupernatants by ELISA. The calculation of CBLB502 amounts that wererecovered during incubation demonstrated that the protein remainedstably associated with ALHYDROGEL in PBS; however, in cell media, 28 and53% CBLB502 was released from the complex at 22° C. and 37° C.,respectively (TABLE F). Such rapid dissociation from ALHYDROGEL in mediamay be facilitated by serum proteins which could displace CBLB502 fromthe complex with alum, explaining how the protein becomes readilyavailable in the cell-based activity assay.

TABLE F CBLB502 recovery from ALHYDROGEL after incubation in PBS andcell media 22° C. 37° C. Incubation CBLB502 dose Total CBLB502 RecoveredDesorption Recovered Desorption conditions μg/100 μl ng/ml ng/ml (%)ng/ml (%) PBS 1 10000 2.3 0.02 33.2 0.33 Media 1 10000 2807.6 28.15300.9 53.0

Example 7: Quantitation of CBLB502 and Cytokine Levels in Mouse Serumafter Subcutaneous Administration of CBLB502/ALHYDROGEL

An animal study was conducted to evaluate feasibility of methods todetermine the levels of CBLB502 and cytokines in serum afteradministration of a CBLB502/ALHYDROGEL formulation. The study design ispresented in TABLE G. In this study, mice were injected subcutaneouslywith a 1 μg dose CBLB502 adsorbed to 52 μl/100 μl ALHYDROGEL 2% andserum samples were collected between 0.5 and 24 hr post inoculation.

TABLE G Study design. Time Age Injection Point, Group Group Strainvolume, blood No. Size Sex Treatment μl collection Evaluation 1 3 8 wkold ALHYDROGEL/PBS, sc 100 1 hr Serum prepared from 2 3 C57BL/6ALHYDROGEL/PBS/CBLB502, 100 30 min collected blood and 3 3 Female (1μg/100 μl CBLB502; 52 100 1 h analyzed for 4 3 μl/100 μl ALHYDROGEL 2%)100 2 h entolimod 5 3 sc 100 4 h concentration and 6 3 100 8 h cytokinelevels by 7 3 100 24 h ELISA

Serum concentrations of CBLB502 were determined by ELISA and were foundat measurable levels in all groups of animals inoculated withCBLB502/ALHYDROGEL. The pharmacokinetic profile representing per-groupmean serum CBLB502 concentrations is shown in FIG. 9. The maximum meanCBLB502 concentration, 0.516 ng/ml, was observed at the first bloodcollection time point, 0.5 hr post administration; the minimumconcentration was 0.012 ng/ml at 24 hr. Half-time elimination of CBLB502was calculated at 2.4 hr. As discussed above, CBLB502 dissociatedrapidly from the complex with ALHYDROGEL after incubation in cell media,containing 10% fetal bovine serum. Therefore, it should be expected tosee the protein released from alum into animal bloodstream shortly afterinoculation.

The concentrations of three cytokines, KC, G-CSF and IL-6, were measuredin the collected mouse serum samples by ELISA (FIG. 10). Rapid inductionof KC and IL-6 was detected 1 hr after CBLB502/ALHYDROGELadministration; the maximum per-group mean concentrations, 29624 and 479μg/ml, respectively, were determined at 2 hr time point. After reachingmaximum, the blood levels of these cytokines decreased to baseline at 4to 8 hr post injection. The serum G-CSF concentration increased about anhour later compared to KC and IL-6 and was maximal between 2 and 4 hrafter CBLB502/ALHYDROGEL administration (7141 and 7169 μg/ml per-groupmean concentrations at 2 and 4 hr, respectively). However,CBLB502-induced G-CSF level was decreasing at a slower rate, remainingabove baseline at 24 hr time point. In general, the kinetics of cytokineinduction after CBLB502/ALHYDROGEL administration was similar to thekinetics observed after injection of the soluble CBLB502 preparations,suggesting consistent effects of this drug formulation.

Example 8: CBLB502 Adjuvant with Methamphetamine Vaccine

This study evaluated CBLB502 adjuvant at a 32 μg dose of humanmethamphetamine vaccine (SMA-TT) to achieve high and long lasting levelsof anti-MA antibody in mice. A low to high dose of CBLB502 ranging from0.03 to 20 μg with TT-SMA and alum was studied. Ten groups (n=5) ofBalb/c female mice were employed to test 0, 0.03, 0.1, 0.3, 1, 3, 10, 20μg of 502 in combination with 32 μg of TT-SMA and 1.5 mg alum comparedto unvaccinated controls and TT-SMA with 502 alone. All vaccinatedgroups were administered two boosters, at 3 and 6 weeks after theinitial vaccination. Levels of anti-MA IgG were assessed by ELISA inpooled sera samples collected at 2, 4, and 6 weeks after initialvaccination. The antibody levels were higher at 0.03 to 0.3 μg 502 incomparison to the higher doses (1 to 20 μg) of 502. In this experiment,antibody levels were 2 fold higher in the groups with 0.1 μg of 502 incombination with TT-SMA and alum (group 4) than in the comparison groupwith TT-SMA and alum alone (group 1) and approx. 4 fold higher whencompared to a group with TT-SMA and 502 alone (group 2), as demonstratedin FIG. 11 (panel A). Anti-502 antibodies in the same sera sample werealso evaluated. As shown in FIG. 11 (panel B), the level of anti-502antibodies was minimal at the low dose range of 502 and increases athigher doses of 502.

Example 9: Generation of Vaccines with Various Antigens

In this Example, the composition of an adjuvant component foradjuvant-enhanced vaccine is established by testing a range of doses ofCBLB502 and CBLB502 optionally combined with an antigen, such as, by wayof non-limitation, NOD1 agonist C12-iE-DAP. Additionally,characterization of the effects of these agents on humoral immuneresponse to a model antigen (ovalbumin) is undertaken.

As shown above, aluminum hydroxide and CBLB502 form a complex which,without wishing to be bound by theory, is stabilized by electrostaticforces as substances with opposite charges in aqueous medium. To testrelative efficacy of different compositions of the adjuvant component ofthe vaccine, a standard dose of aluminum is used (1.5 μg per injection)loaded with a range of doses of CBLB502 (up to 30 μg and including 10μg, 3 μg, 1 μg, 0.3 μg and 0.1 μg). CBLB502 in aqueous solution is addedto the alum suspension in PBS and stirred for 10 min at roomtemperature. Aluminum hydroxide is then spun down by centrifugation andtraces of CBLB502 in supernatants are determined using two quantitativeanalytical assays: (i) ELISA-based and (ii) reporter cell based(TLR5-positive 293 cells carrying NF-κB responsive reporter andcalibrated for detection of CBLB 502 in the medium). In light of, interalia, the above Examples, it is expected that a substantial fraction ofCBLB 502 will be stably bound to alum under these conditions and withinthe chosen range of doses of TLR5 agonists.

To determine whether this adjuvant remains localized at the vaccineinjection site, adult BALB/c female mice (n=10) carrying in their germline firefly luciferase cDNA under the control of NF-κB-responsivepromoter will be used. These “NF-κB reporter mice” are a sensitive toolfor the detection of release of CBLB502 from the injection site bymonitoring the luciferase activity in TLR5-positive tissues such asliver or small intestine. Only one dose of CBLB502-containing adjuvantformulation will be used that corresponds to the highest dose thatdemonstrated stability as a composition with Alum in vitro (presumably30 μg). Two doses of free CBLB502 (1 and 3 μg in aqueous solution, s.c.injection) will be used for comparison as positive controls ofsystemically distributed TLR5 agonist. Luciferase detection will be doneusing a luminescent imager in vivo following luciferin injection at 2,4, 6 and 18 hours post injection of the adjuvant. For a more accurateand sensitive detection, 3 animals from each group are sacrificed 6hours post injection of the adjuvant formulation and tissues will becollected from the injection site, lymph nodes nearest to injection siteand the liver. The level of luciferase activity indicative of thepresence of CBLB 502 is quantitated in these tissue samples followingtissue lysis. In addition to functional detection of CBLB 502 based onits expected NF-κB-inducing activity, an alternative analytical methodof an established sensitive ELISA assay for direct detection of CBLB502in tissue extracts is used.

Adjuvant formulations containing the above-described range of doses ofCBLB502 are mixed with 10 mg of ovalbumin and vaccination is performed,as described herein, followed by the ELISA determination of titers ofdifferent classes of anti-albumin IgG (IgG1, IgG2a, IgG2b and IgG3)antibodies. The results are compared with “Alum only” control.Determination of the effects on different IgG types provides definitionof the degrees of engagement of different immunization paths (e.g.T_(H1)-versus T_(H2)-mediated routes) by the adjuvant.

After determination of the composition of the adjuvant (in terms ofanti-ovalbumin antibody inducing efficacy), additional enhancement ofimmunization is tested by adding into the formulation a NOD1 agonist,C12-iE-DAP.

Also, determination of vaccine efficacy at different CBLB 502 doses togenerate antibodies to antigen is undertaken in mice. Female mice arechosen because they have stronger immune responses than male mice andBALB/c mice are a commonly used strain in immunological studies due totheir robust immune responses. At the beginning of the study, mice weighabout 25 g and are group-housed (5 per cage) in standard acrylic cages(7″×11″×5″) with corncob bedding polycarbonate and tops. Mice will havead libitum access to food (Harlan) and water. The vivarium will bemaintained at 22±1° C. and on a 12:12 light/dark cycle (lights on at 6AM). All experimental procedures are approved by the InstitutionalAnimal Care and Use Committee (IACUC) and are within the guidelinesdelineated in the Guide for the Care and Use of Laboratory Animals.

Mice are intramuscularly injected with the vaccine in the glutealmuscle. Each group is optionally immunized with a booster dose with thesame vaccine formulation at 3 and 6 weeks post initial immunization. Ifpersistent antibody levels are not maintained for at least 4 weeks, anadditional immunization will be given at week 10.

Blood is drawn at 14, 28, 42, 56 and 84 days post initial immunizationand allowed to clot at room temperature for 2 hours. Serum is collectedafter centrifugation at 4000 rpm for 15 min. Samples are stored at −80degrees until ready to run the enzyme linked immunosorbant assays(ELISA). In the context of a vaccine with antigen X, anti-antigen Xspecific antibodies are assessed by ELISAs. To measure the antibodies,ELISA plates (Immulon 2HB, Daigger, Vernon Hills, Ill.) are coatedovernight in carbonate buffer (0.05 M; pH 9.6) using fish gelatin, whichis a heterologous carrier protein, as the conjugate partner for SMA.Pooled or individual serum samples are added to plates in 2 fold serialdilutions starting at 1K in phosphate buffered saline (PBS)-Tween (0.1%)and incubated for 2 hours. Plates are washed with PBS-Tween prior toadding goat anti-mouse IgG conjugated to horse-radish peroxidase (HRP)(Southern Biotech, Birmingham, Ala.). Plates are incubated for another30 min and washed before adding substrate (Tetramethylbenzidine, Sigma,St. Louis, Mo.). Plates are incubated for 45 min in the dark prior tostopping the reaction with 1M HCl. The optical density (OD) of theresulting dark spots on the plates from the antibody with antigen Xlinking are used to measure titer levels on a microplate reader (iMarkMicroplate Absorbance Reader) using Microplate Manager v 6.1 software.

ELISA data is analyzed using SigmaPlot (Systat Software Inc.) andbackground antibody binding to the carrier alone will be subtracted fromeach sample. Comparisons are made in each plate with a standard curve ofpurified mouse IgG (Sigma) bound directly in the wells in serialdilution.

Example 10: Comparison of CBLB502-Based Adjuvants/Vaccines withFlagellin-Based Adjuvants/Vaccines

The CBLB502/alum adjuvant of the above Examples is tested head to headagainst a flagellin/alum adjuvant using the methods and study design of,for instance, Example 9 (optionally with an antigen). Further, the alumbinding and dissociation studies, as well as the mouse evaluationstudies, all described in the above Examples, are repeated with aflagellin/alum adjuvant for comparison to the CBLB502/alum adjuvant. Theefficacy of the CBLB502 variant, i.e., CBLB502-S33MX is also tested.

In one comparison experiment, a group of mice (n=6) is immunized withTT-SMA, which is a methamphetamine vaccine and is used illustratively,co-adsorbed onto Alhydrogel with either flagellin, CBLB502, orCBLB502-S33MX. Immunication is carried out on days 0, 14, and 28 of thestudy. Each immunization dose includes 32 μg of TT-SMA and adjuvants asfollows: Group 1: 0.03 μg flagellin, Group 2: 0.1 μg flagellin, Group 3:0.3 μg flagellin, Group 4: 1 μg flagellin, Group 5: 0.03 μg CBLB502,Group 6: 0.1 μg CBLB502, Group 7: 0.3 μg CBLB502, Group 8: 1 μg CBLB502,Group 9: 0.03 μg CBLB502-S33MX, Group 10: 0.1 μg CBLB502-S33MX, Group11: 0.3 μg CBLB502-S33MX, and Group 12: 1 μg CBLB502-S33MX.

Serum samples are collected and analyzed on days −1 (pre-immune serum),14 (post-prime), 28 (post first boost), and 35 (post second boost). Forexample, the serum samples are analyzed for the levels ofanti-methamphetamine and anti-entolimod antibodies. Analysis indicatesthat CBLB502/alum and CBLB502-S33MX/alum cause a broader, more diverse,more robust and longer immunostimulatory effect than flagellin/alum. Inaddition, CBLB502/alum and CBLB502-S33MX/alum activate both T_(H1) andT_(H2)-mediated immune response and a greater T_(H1)-mediated immuneresponse than flagellin/alum.

EQUIVALENTS

While the invention has been described in connection with specificembodiments thereof, it will be understood that it is capable of furthermodifications and this application is intended to cover any variations,uses, or adaptations of the invention following, in general, theprinciples of the invention and including such departures from thepresent disclosure as come within known or customary practice within theart to which the invention pertains and as may be applied to theessential features hereinbefore set forth and as follows in the scope ofthe appended claims.

Those skilled in the art will recognize, or be able to ascertain, usingno more than routine experimentation, numerous equivalents to thespecific embodiments described specifically herein. Such equivalents areintended to be encompassed in the scope of the following claims.

INCORPORATION BY REFERENCE

All patents and publications referenced herein are hereby incorporatedby reference in their entireties.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.

As used herein, all headings are simply for organization and are notintended to limit the disclosure in any manner. The content of anyindividual section may be equally applicable to all sections.

REFERENCES

-   1. Yoon S I, Kurnasov O, Natarajan V, Hong M, Gudkov A V, Osterman A    L, Wilson I A., 2012. Structural Basis of TLR5-Flagellin Recognition    and Signaling. Science 335:859-864 (PMID: 22344444)-   2. Smith K D, Andersen-Nissen E, Hayashi F, Strobe K, Bergman M A,    Barrett S L, Cookson B T, Aderem A. 2003. Toll-like receptor 5    recognizes a conserved site on flagellin required for protofilament    formation and bacterial motility. Nat Immunol. 4:1247-53 (PMID:    14625549)-   3. Mizel, S. B., A. P. West, R. R. Hantgan. 2003. Identification of    a sequence in human Toll-like receptor 5 required for the binding of    Gram-negative flagellin. J. Biol. Chem. 278:23624-23629 (PMID:    12711596)-   4. Murthy, K. G., Deb, A., Goonesekera, S., Szabo, C. &    Salzman, A. L. (2004) J. Biol. Chem. 279:5667-5675 (PMID: 14634022)-   5. Andersen-Nissen E., Smith K. D., Strobe K. L., Barrett S. L.,    Cookson B. T., Logan S. M., Aderem A. (2005) Evasion of Toll-like    receptor 5 by flagellated bacteria. Proc. Natl. Acad. Sci. U.S.A.    102: 9247-9252 (PMID: 15956202)-   6. Andersen-Nissen E, Smith K D, Bonneau R, Strong R K,    Aderem A. 2007. A conserved surface on Toll-like receptor 5    recognizes bacterial flagellin. J Exp Med. 204:393-403 (PMID:    17283206)-   7. Burdelya L G, Krivokrysenko V I, Tallant T C, Strom E, Gleiberman    A S, Gupta D, Kurnasov O V, Fort F L, Osterman A L, Didonato J A,    Feinstein E, Gudkov A V., 2008. An agonist of Toll-like receptor 5    has radioprotective activity in mouse and primate models. Science    320:226-230 (PMID: 18403709).-   8. Huleatt J W, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang    J, McDonald W, Song L, Evans R K et al. 2008. Potent immunogenicity    and efficacy of a universal influenza vaccine candidate comprising a    recombinant fusion protein linking influenza M2e to the TRL5 ligand    flagellin. Vaccine. 26:201-214.

What is claimed is:
 1. A method of vaccinating a subject against adisorder, comprising administering an effective amount of a vaccinecomprising: (a) an adjuvant comprising: a flagellin-based agentcomprising an amino acid sequence having at least 95% identity with oneof SEQ ID NO: 35, 71, and 150, and an aluminum gel or salt, wherein theratio (w/w) of flagellin-based agent to aluminum gel or salt is about1:500 or less and (b) an antigen which stimulates protective immunityagainst the disorder, wherein the antigen is a constituent of aninfectious agent selected from a live and attenuated, killed,inactivated, and toxoid infectious agent; and wherein the disorder isselected from infectious diseases, cancers, and allergies.
 2. The methodof claim 1, wherein the disorder is selected from diphtheria, tetanus,pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellowfever, Human Papillomavirus (HPV) infection, anthrax, rabies, JapaneseEncephalitis, meningitis, measles, mumps, rubella, gastroenteritis,smallpox, typhoid fever, varicella (chickenpox), rotavirus, andshingles.
 3. The method of claim 1, wherein the flagellin-based agentcomprises the amino sequence of one of SEQ ID NO: 35, 71, and
 150. 4.The method of claim 1, wherein the flagellin-based agent inhibits andabrogates the ability of neutralizing anti-flagellin antibodies toneutralize the adjuvant.
 5. The method of claim 1, wherein the aluminumgel or salt is selected from aluminum hydroxide, aluminum phosphate, andaluminum sulfate.
 6. The method of claim 1, wherein one or more of theflagellin-based agent and/or the antigen is adsorbed to the aluminum gelor salt.
 7. The method of claim 1, wherein the flagellin-based agent andaluminum gel or salt are mixed to form a stable complex.
 8. The methodof claim 1, wherein the flagellin-based agent and aluminum gel or saltare mixed in a ratio that is substantially below a loading capacity ofthe aluminum salt.
 9. The method of claim 8, wherein the flagellin-basedagent and aluminum gel or salt are mixed in a ratio (w/w) of about1:500, or about 1:600, or about 1:700, or about 1:800, or about 1:900,or about 1:1000, or about 1:2000, or about 1:5000, or about 1:10000. 10.The method of claim 1, wherein the antigen is that of one or more of thefollowing vaccines: DTP (diphtheria-tetanus-pertussis vaccine), DTaP(diphtheria-tetanus-acellular pertussis vaccine), Hib (Haemophilusinfluenzae type b) conjugate vaccines, Pneumococcal conjugate vaccine,Hepatitis A vaccines, Poliomyelitis vaccines, Yellow fever vaccines,Hepatitis B vaccines, combination DTaP, Tdap, Hib, Human Papillomavirus(HPV) vaccine, Anthrax vaccine, and Rabies vaccine.
 11. The method ofclaim 1, wherein the vaccine further comprises an additional adjuvantselected from oil-in-water emulsion formulations, saponin adjuvants,ovalbumin, Freund's Adjuvant, cytokines, and chitosans.
 12. The methodof claim 1, wherein the vaccine and/or adjuvant causes immunostimulationof one or more of a T_(H1) and T_(H2)-mediated immune response.
 13. Themethod of claim 1, wherein the administering is orally or by parenteralinjection.
 14. The method of claim 1, wherein the administering takesplace by controlled-release or sustained-release.
 15. The method ofclaim 1, wherein the vaccine is administered once per subject or is usedin a booster strategy.